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Abstract 
The incredible flexibility and specificity of the humoral immune response is dependent 
on the highly diverse repertoire of naïve and affinity-matured antibodies. Utilizing and 
understanding the power of this response requires high-throughput approaches. This thesis 
describes three projects that use recent advances in DNA sequencing and synthesis to develop 
and apply methods to probe the diversity of these responses at unprecedented depth. Chapter 2 
describes a synthetic antibody library designed for high-throughput sequencing assisted selection 
which enables rapid in vitro selection of antibodies that bind specifically to a target of interest by 
bypassing the need for laborious single-clone screening for specific binding. Chapter 3 describes 
a high-throughput assay for detection of antibodies against all known human viruses using 
immunoprecipitation and high-throughput sequencing of bacteriophage displaying a library of 
peptides tiling through the proteome of all known human viruses. And last, chapter 4 describes 
the use of immunoprecipitation and high-throughput sequencing of both bacteriophage displayed 
peptides from the human peptidome and ribosome displayed proteins from the human proteome 
to identify a novel subclass of patients with scleroderma with autoantibodies against the minor 
spliceosome complex. The work described in this thesis will enhance our ability to study and 
exploit the properties of antibodies and the humoral immune response. 
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Chapter&1:&
Introduction&
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Immunity(depends(on(molecular(recognition(by(specialized(proteins(
The human immune system is composed of a complex series of processes mediated by 
highly specialized cells, soluble factors, and physiological compartments. It is tasked with 
defending the body from invasion by both external threats, such as microorganisms and 
parasites, and internal threats, such as malignancies. To achieve this purpose, the immune system 
has a variety of powerful mechanisms for selectively controlling, killing, and eliminating 
invaders. These mechanisms must be tightly controlled to prevent unintended damage.  
The basis of this control is discrimination between “self” and “non-self”. “Self” 
encompasses all of the normal, healthy components that make up the host, whereas “non-self” 
can be almost anything else. As I will discuss further, the adaptive immune system is capable of 
recognizing an astounding diversity of “non-self” targets with exquisite precision. By limiting its 
destructive processes to “non-self” targets, the immune system can eliminate threats without 
damaging the body. 
At the molecular level, recognition of “non-self” is mediated by proteins that bind 
specifically to molecular structures found only on “non-self” targets and not on the “self” (1). 
Both the innate and the adaptive branches of the immune system contain a variety of these 
recognition proteins. 
The innate immune system uses germ-line encoded soluble proteins, such as mannose-
binding lectins, and cell membrane associated pattern recognition receptors, such as Toll-like 
receptors, that recognize conserved pathogen associated molecular patterns and damage 
associated molecular patterns that are not normally found on undamaged “self” tissues (2).  
Diversity(of(antibodies(enables(flexible(recognition(
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The adaptive immune response, as its name suggests, is able to adapt the proteins it uses 
for recognition to novel molecular patterns that no germline-encoded protein is able to recognize. 
This remarkable flexibility arises from somatic recombination and mutation of a set of modular 
immunoglobulin gene segments that come together to form an incredibly diverse set of 
recognition proteins (3). In general, each round of recombination and/or mutation results in a 
clonal cell lineage that expresses a particular adaptive recognition protein with a unique 
specificity. The cells that produce these proteins can either be B cells, which secrete soluble 
antibody proteins that recognize extracellular targets (antigens), or T cells, which recognizes 
complexes of a specific peptide bound to a specific major histocompatibility complex (MHC) 
protein. 
In this dissertation, I will focus on the humoral immune response, which is mediated by 
antibodies secreted by B cells. At any one time, each person harbors over 1011 B cells (4), each of 
which could be expressing an antibody from the over 1013 different theoretically achievable 
specificities (5). Maintaining such a diverse antibody repertoire increases the probability that at 
least one of them will be able to recognize any newly encountered antigen. Indeed, B cells can 
generate antibody responses against everything from small molecules, to proteins, to 
polysaccharides (6).  
High;throughput(sequencing(enables(study(of(antibody(diversity(
However, the incredible repertoire diversity that makes the antibody response so 
powerful also makes it extremely difficult to study. Traditional techniques for studying 
antibodies and their specificity, including hybridoma cloning, ELISA assays, and Sanger 
sequencing of antibody genes, are generally limited to assaying single or at most hundreds of 
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antibody-antigen interactions. With these technologies, it was simply not feasible to study the 
antibody response at any appreciable complexity. 
In the past two decades, rapid advances in high-throughput DNA sequencing technology 
have led to novel methods for interrogating the diversity of antibody gene sequences at 
unprecedented depth (7). Since 1990, the per-nucleotide cost of DNA sequencing has decreased 
by almost seven orders of magnitude (8). This precipitous drop in price enabled several studies 
that were previously infeasible due to cost considerations. The results of these studies have 
broadened our understanding of the development of the humoral immune response and its 
function in a variety of settings, including infectious disease, cancer, autoimmunity, and immune 
deficiency (7).  
High;throughput(sequencing(also(improves(selection(of(synthetic(
antibodies(
These studies used high-throughput sequencing to examine the properties of pre-existing 
antibody responses. In Chapter 2, I discuss our work on using high-throughput sequencing to 
discover new antibodies that bind specifically to targets of interest. Because of their incredible 
specificity and affinity, antibodies have become indispensable tools for research, diagnostics, and 
therapeutics. In fact, monoclonal antibodies made up five of the top ten pharmaceutical products 
by sales volume in 2014 (9).  
These antibodies are usually created either in vivo, by immunizing an animal with the 
target of interest, or in vitro, by using the target of interest to perform affinity purification of a 
library of synthetic antibodies (10). The in vitro method is generally simpler and faster because it 
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does not require animal husbandry or complex immunization protocols, but both methods result 
in a population of antibodies, of which only a portion will bind the target specifically.  
Identifying the desired antibodies requires laborious screening of hybridomas or clonal 
species to ascertain their ability to specifically bind the target of interest. If the desired antibodies 
are not present at a significant proportion of the population, it may be necessary to screen an 
extremely large number of clones or perform additional immunizations or selections. 
Because antibodies play such a critical role in research, diagnostics, and therapeutics, 
there is significant interest in simpler techniques to rapidly create antibodies against a range of 
targets. In particular, completion of the human genome sequence provided a catalogue of 
components of the human proteome, but the tools for studying these proteins are still lacking in 
comprehensiveness and quality. In response, several groups, including the Human Protein Atlas 
(11) and the Human Antibody Initiative (12), have sought to work collectively on developing a 
collection of monoclonal antibodies against each protein in the human proteome. Increasing the 
throughput of methods to create these antibodies would greatly enhance the ability to develop a 
comprehensive toolbox for proteomics research. 
In our work, we develop an in vitro synthetic antibody library that was designed to use 
high-throughput sequencing to monitor enrichment (as a proxy for binding activity) of specific 
antibody clones in the entire population across multiple rounds of affinity purification to identify 
desired antibodies without the need for laborious clonal screening (13). The synthetic antibody 
library was designed using a common immunoglobulin framework and contained sequence 
diversity only in the relatively short complementarity determining regions so the identity of any 
member of the library could easily be obtained by sequencing these regions.  
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Since modern high-throughput sequencers can routinely sequence over 108 individual 
DNA molecules, this library design enables quantification of the relative abundance of each 
antibody in a very complex mixture. Antibodies that bind specifically are easily identified as the 
ones whose relative abundance increases after affinity purification on the target of interest but 
not a non-specific target. This analysis can be performed purely using the sequencing data and 
can detect antibodies at very low abundance without having to resort to laborious clonal 
screening. We demonstrated the application of this method to select a specific antibody against 
an antigen implicated in breast cancer cell transformation. The sequencing-assisted antibody 
library design and selection method we describe can be used to rapidly create antibodies that 
bind specifically to a target of interest and will enable more rapid development of tools for 
proteomic research, diagnostic assays, and therapeutic biologics. 
Identification(of(an(unknown(antibody’s(antigen(is(important(but(
difficult(
Sequencing the genes encoding antibodies reveals the identity of the antibody, but it does 
not reveal the identity of the antigen the antibody recognizes. Despite recent progress in 
computationally modeling of the structure of immunoglobulins based on their amino acid 
sequence (14) and docking simulations to assess molecular interactions (15), predicting whether 
an antibody binds to a target based on sequence and structure alone are still extremely difficult 
and existing methods are usually inaccurate (16).  
Thus, although high-throughput sequencing of the genes encoding antibodies has greatly 
increased the ability to study how individual antibody sequences arise and evolve, another 
method is required to study the antigen targets of these antibodies. The identity of the antigen 
targets often has greater clinical significance than the identity of the antibody. Multiple 
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antibodies with differing gene sequences could recognize the same or different regions on the 
same antigen, and knowing that any antibodies against an antigen exist can provide clinical 
insight into pathogen exposure and underlying disease processes. For example, if the antigen is a 
viral protein, the existence of antibodies against the antigen suggests prior infection. Or if the 
antigen is a self-protein, it could be suggestive of autoimmunity. 
Because people are exposed to a diverse array of antigens in the environment and generate 
antibodies that could potentially target any number of those antigens, high-throughput 
technologies are required to determine which antigens the antibodies recognize. To test all of the 
possible antibody-antigen interactions, it is necessary to have a collection of all of the potential 
antigens of interest. Traditionally, in order to construct these collections in a cost-effective 
manner, researchers have turned to cDNA libraries of antigens and affinity purification using the 
unknown antibody or antibody mixture (17). However, the representation of each antigen in a 
cDNA library can vary wildly depending on its expression level and some antigens may not even 
be present if the protein is not expressed in the source RNA material (18). With such skewed 
libraries, it can be difficult or impossible to detect interaction between the antibody and an 
antigen that is expressed at very low or non-existent levels. 
Advances(in(DNA(synthesis(enables(technologies(to(identify(
antibody;antigen(interactions(
Instead of creating the antigen collection from natural material, recent advances in DNA 
synthesis have enabled the creation of fully synthetic representations of the antigen collection 
that are comprehensive and uniform (19). Reminiscent of the rapid decline in cost of DNA 
sequencing, the per-nucleotide price of oligonucleotide synthesis has dropped by over 7 orders of 
magnitude in the past three decades (8). These rapid advances in oligonucleotide synthesis have 
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largely been driven by the development of DNA microarray technologies that apply micro- and 
nanofabrication techniques to solid-phase nucleotide synthesis chemistries. Modern iterations of 
these technologies can synthesize over 105 custom oligonucleotides of up to hundreds of 
nucleotides in length at a price affordable to single researchers. 
As was seen with the rapid advances in high-throughput sequencing, breakthroughs in 
DNA synthesis have also enabled a wide variety of new technologies that have transformed 
multiple fields of study (20). In this thesis, I will focus on their application in creating synthetic 
representations of protein antigens to study antibody-protein interactions. 
In Chapter 3, I present work on the construction and validation of VirScan, an approach 
to comprehensively study the human antiviral antibody response using a library of viral protein 
fragments encompassing all known human viruses and its application in studying the antiviral 
antibody response across large populations. Viruses are traditionally considered purely in the 
context of pathogenesis, but recent studies have shown that human viruses are able to modulate 
host immunity by a variety of much more subtle mechanisms. In addition, vaccinations or 
productive infections can elicit long-lived plasma cells that can continue secreting their 
antibodies for decades (21). Thus, the immunological imprint on the circulating antibody 
repertoire left by the virus serves as a record of virus exposure and a window into the 
interactions between host immunity and viral infection. 
Traditional methods to study the antiviral antibody repertoire, such as enzyme-linked 
immunosorbent assay (ELISAs), are generally limited to testing single or at most hundreds of 
antibody-virus or antibody-viral antigen interactions. Recently, viral metagenomic sequencing 
studies, enabled by the rapid advances in high-throughput DNA sequencing, have revealed that 
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humans are colonized or exposed to a highly complex collection of viruses (22). Studying the 
antibody response against all of these viruses and, in particular, all of the viral antigens are 
infeasible using standard techniques. 
Instead, we took the approach of using the capabilities of microarray DNA synthesis and 
bacteriophage display to create a synthetic representation of protein fragments tiling through the 
proteomes of all human viruses that have been uncovered by DNA sequencing. Similar to the 
work in Chapter 2, we designed this library to be compatible with high-throughput sequencing, 
so that we could identify which viral antigens are targeted by a mixture of antibodies simply by 
using sequencing to find which antigens’ relative abundances are increased after affinity 
purification with the antibodies. This approach enables comprehensive study of the humoral 
antiviral response in antibody samples from a large number of human donors. It incorporated 
many elements from Phage Immunoprecipitation-Sequencing (PhIP-Seq), a technology 
developed previously by our laboratory, and discussed in the following paragraphs (19). 
In Chapter 4, I present the work on identifying a novel subclass of patients with the 
autoimmune disease scleroderma who have autoantibodies against the minor spliceosome 
complex. This work used both PhIP-Seq and a complementary approach, Parallel Analysis of 
Translated Open Reading Frames (PLATO) (19, 23). Both technologies combine a collection of 
synthetic DNA encoded proteins and high-throughput sequencing to identify human autoantigens 
recognized by autoantibodies. PhIP-Seq is the predecessor of VirScan and pioneered the concept 
of combining high-throughput sequencing assisted affinity purification and a bacteriophage 
display library of protein fragments encoded by oligonucleotides synthesized on DNA 
microarrays. As such, it also has the advantages that VirScan has over traditional antibody-
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antigen assays. However, because it uses protein fragments rather than full-length proteins, PhIP-
Seq may miss antibodies that recognize discontinuous epitopes that cannot be capture by a 
protein fragment. PLATO overcomes this limitation by using ribosome display of full-length 
proteins, but its coverage of the human proteome is incomplete at present. Thus, combining these 
complementary technologies provides a powerful approach to identifying autoantigens. 
Scleroderma is an autoimmune rheumatic disease of unknown etiology (24). Traditional 
serum ELISA and immunoprecipitation-Western blot assay have identified three mutually 
exclusive subclasses of patients with scleroderma who have autoantibodies against the 
centromere, topoisomerase 1, or RNA polymerase III (Pol III) (25). Intriguingly, patients in the 
subclass with autoantibodies against Pol III are also frequently diagnosed with coincident cancer 
and a recent study suggests the anti-Pol III autoantibodies may be due to a cross-reactive 
immune response against a tumor neoantigen in the gene encoding Pol III (26, 27).  
A significant percentage of patients with scleroderma do not fall into these subclasses and 
the targets of their autoantibodies are largely unknown. Interestingly, many of these patients are 
also diagnosed with coincident cancer. (27) We hypothesized that there are novel subclasses of 
patients with shared autoantibodies that arise due to the same tumor-associated cross-reactivity 
as the Pol III subclass so we used PhIP-Seq and PLATO to search for these novel autoantigen 
subclasses.  
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Abstract(
Antibody discovery platforms have become an important source of both therapeutic 
biomolecules and research reagents. Massively parallel DNA sequencing can be used to assist 
antibody selection by comprehensively monitoring libraries during selection, thus greatly 
expanding the power of these systems. We have therefore constructed a rationally designed, fully 
defined single-chain variable fragment (scFv) library and analysis platform optimized for 
analysis with short-read deep sequencing. Sequence-defined oligonucleotide libraries encoding 
three complementarity-determining regions (L3 from the light chain, H2 and H3 from the heavy 
chain) were synthesized on a programmable microarray and combinatorially cloned into a single 
scFv framework for molecular display. Our unique complementarity-determining region 
sequence design optimizes for protein binding by utilizing a hidden Markov model that was 
trained on all antibody-antigen cocrystal structures in the Protein Data Bank. The resultant 
∼1012-member library was produced in ribosome-display format, and comprehensively analyzed 
over four rounds of antigen selections by multiplex paired-end Illumina sequencing. The hidden 
Markov model scFv library generated multiple binders against an emerging cancer antigen and is 
the basis for a next-generation antibody production platform. 
Introduction(
Antibodies are useful for their ability to bind molecular surfaces with high affinity and 
specificity. The genetic basis for their structural diversity is partially encoded in the germ line, 
but is also the result of stochastic genetic events, including chromosomal rearrangements, 
nontemplated nucleotide insertions, and somatic hypermutation. The majority of this diversity is 
localized to the complementarity-determining regions (CDRs), which are the six-peptide loops 
that protrude from the variable domain framework to form the antigen-combining surface of the 
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antibody molecule. Three CDR loops are contributed by the heavy chain (H1, H2, and H3) and 
three by the light chain (L1, L2, and L3). CDRs 1 and 2 are encoded in the germ line, and are 
thus more constrained in their diversity. L3 is characterized by “junctional diversity,” formed 
during the recombination of two gene segments (V and J). Finally, H3 is formed by two 
consecutive genetic rearrangements (first between D and J, and then between V and DJ), and is 
additionally accompanied by nontemplated “N” nucleotides, making this CDR the source of 
most naturally occurring antibody diversity. 
Our goal was to develop a synthetic antibody production platform inspired by nature, 
which could be seamlessly integrated with massively parallel, short-read DNA sequencing 
analysis (Figure 1A) (28, 29). For maximum convenience, we required that library amplification 
and sequencing reactions should depend upon a single set of primers, rather than the complex 
mixture necessary for natural repertoire amplification and analysis. Like others before, we 
therefore constructed a highly diverse antibody library within a single variable-domain 
framework (30, 31). However, because it is well known that the natural diversity of variable-
domain frameworks contributes to a naive repertoire’s functional shape space (32, 33), we 
sought to maximize the functional diversity in our library’s CDR repertoire by rationally 
designing sequences based on a mathematical model of antibody–antigen interaction.  
A single-chain variable fragment (scFv) is the simplest functional representation of an 
antibody molecule, and has become the platform of choice for most antibody engineers. Our first 
step was thus to identify the most suitable scFv framework to house libraries of rationally 
designed CDRs. Lloyd et al. screened a very large preimmune human scFv library against a 
panel of 28 different antigens, and after sequencing >5,000 postselection clones, they observed 
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strong enrichment of a small subset of heavy- and light-chain variable domains (34). Among 
these domains, the most highly enriched were the heavy chain VH1–69 and the λ-light chain 
VL1–44. The authors attributed these framework enrichments to increased expression and 
optimal folding within the periplasm of the Escherichia coli host cells. These findings were 
further corroborated by the work of Glanville and colleagues (35). We therefore housed our CDR 
libraries within an scFv framework composed of VH1–69 and VL1–44. 
As a source of inspiration for CDR design features, we looked to the international 
ImMunoGeneTics’ (IMGT’s) annotated database of all antibody–antigen cocrystal structures 
present within Protein Data Bank (IMGT/3Dstructure-DB) as of May 2009 (36, 37). Amino acid 
residues within CDRs can contribute to antigen binding in two distinct ways: (i) direct, via 
contribution of a side group that makes contacts with the antigen, and (ii) indirect, affecting the 
conformation of the peptide backbone in a way that permits the direct interaction of neighboring 
amino acid side groups. This behavior of CDR amino acid sequences can be captured in a two-
state hidden Markov model (HMM). The “contact” state should be enriched for amino acids 
capable of sharing/exchanging electrons or burying hydrophobic surfaces, whereas the 
“noncontact” state should be enriched for residues capable of appropriately constraining or 
relaxing the CDR polypeptide backbone. An important feature of HMMs is that the state of each 
position depends upon its nearest neighbor. It is thus important to note that traditional 
approaches to synthetic CDR construction typically use degenerate nucleotides or codons, and so 
cannot link the identity of a particular residue to that of its neighbors. To implement our HMM 
design, we took a different approach and synthesized complete CDR sequences as releasable 
oligonucleotides on a programmable DNA microarray. Importantly, this approach permits the 
filtering of deleterious sequences, such as restriction sites and undesirable peptide motifs (e.g., 
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Figure 1. HMM antibody library design and synthesis. (A) Strategy for design and application of the rationally 
designed scFv library. Antigen–antibody crystal structures are used to design CDR-encoding DNA sequences, which 
are then synthesized on a programmable microarray. After ribosome display and enrichment for antigen binding 
clones, library recovery, and analysis by paired-end sequencing can be performed. (B) Model-defining parameters 
for the L3 HMM. Emission probability for each amino acid corresponding to the two possible states. State transition 
probabilities are inset: “S” denotes start of a chain, “C” denotes the contact state, “N” denotes the noncontact state, 
“E” denotes the end of the chain. (C) Model-defining parameters for the H3 HMM. Definitions are the same as for 
B. (D) Overview of the scFv ribosome display vector and library assembly strategy. “VL” and “VH” are the light 
and heavy variable domains, respectively. “T7 prom” is the T7 promoter, and the crossed stop sign denotes lack of a 
stop codon. L3, H2, and H3 are the CDR libraries designed to replace the “SI” suicide inserts. H3L and H3R 
sublibraries are brought together by combinatorial ligation to create H3. Similarly, the L3-H2 fragment is brought 
together with the H3 fragment in a combinatorial ligation. (E) Clonal Sanger sequencing analysis of 93 HMM scFv 
library members. 
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glycosylation signals and good HLA class II substrates), thus maximizing the functional utility of 
the library. 
The transformation efficiency of bacterial cells with plasmid DNA is a significant barrier 
to construction of molecular libraries with a complexity greater than ∼1010. Because the utility 
of an scFv library scales with its diversity, we took advantage of the in vitro ribosome display 
technique, which has been used to generate antibodies with picomolar affinities (38). In this 
approach, mRNA molecules are tethered to the proteins they encode via noncovalent interactions 
with a ribosome. The mRNA is made to lack a stop codon necessary for peptide release, and so a 
population of ternary complexes composed of mRNA, encoded scFvs, and ribosomes is thus 
formed. Ribosome display libraries can be constructed and transcribed entirely in vitro, thus 
bypassing transformation bottlenecks. 
After characterizing the quality of the HMM scFv library, we tested it by sequencing the 
library as it evolved over multiple rounds of selection on a protein antigen. We also developed 
robust methods to specifically recover desirable clones for expression and analysis in a simple 
two-step process. Our platform successfully produced antibodies against the emerging cancer 
antigen poliovirus receptor-related 4 (PVRL4) and sets the stage for a new paradigm in 
sequencing-assisted selection of rationally designed human antibodies. 
Results(
Library(Design,(Assembly,(and(Characterization(
We set out to diversify the three CDR loops most relevant to antigen binding. By 
examining the IMGT/3Dstructure-DB, we determined the average number of contacts per 
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structure contributed by each CDR. Of contacts reported in this database, 76% are contributed by 
residues contained within CDRs. As expected, L3 and H3 contribute the most contacts, with H2 
providing the third-most. In sum, 71% of CDR contacts are made by amino acids in these three 
CDRs (Figure 2A). 
To estimate the HMM-defining parameters for L3 and H3, we identified 236 unique L3 
and 241 unique H3 sequences within IMGT/3Dstructure-DB. Each residue was classified as 
either making contact or not with the protein antigen, as determined by the corresponding 3D 
cocrystal structure. The resulting HMM state transition rates and amino acid emission 
probabilities for L3 and H3 are illustrated in Figure 1B and C. Notable features of these models 
are: (i) enrichment for the noncontact state at positions closer to the framework [i.e., probability 
of S (start) → N (noncontact) and N → E (end) transitions are much greater than S → C 
(contact) and C → E, respectively]; (ii) in H3, a tendency for blocks of contact/noncontact states 
(i.e., probability of staying in the same state is higher than transitioning between states); (iii) a 
strong enrichment in both L3 and H3 for contacts consisting of tyrosine and tryptophan 
[previously observed by Ofran et al. (39)]; and (iv) L3- or H3-specific enrichments for certain 
amino acids in each state (e.g., noncontact proline in L3, and contact glutamic acid in H3). 
We used our HMM to generate >10,000 unique sequences for each of L3 and H3 (40). 
Whereas the length of L3 sequences was fixed at 13 residues, 1,000 H3 sequences were 
randomly chosen for each length from 9 to 21 amino acids long. As an analog to VJ 
recombination, we further expanded the diversity of H3 by separating each sequence into two 
halves: “H3L” and “H3R,” for subsequent combinatorial ligation to form full-length H3 
sequences (Figure 1D). This was accomplished by placing a type IIS restriction site downstream 
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of H3L and upstream of H3R on their encoding oligos. After PCR and restriction digest with the 
SapI restriction endonuclease, the H3L and H3R fragments were combinatorially ligated 
together. The 3-nt 5′ SapI overhang on each sublibrary ensured that the H3 reading frames would 
remain intact. 
The germ-line–encoded H2 CDR is characterized by structural features not present in L3 
or H3 chains, and this is reflected in its heterogeneous contact profile (Figure 2B). It has been 
suggested that H2 contributes to the stability of the variable domain of the heavy chain through 
interactions among its hydrophobic residues (41, 42). To avoid disrupting framework stability, 
we created a first-order Markov chain to generate H2 sequences that was trained on the 176 
unique H2 chains in the IMGT database. This model was used to generate >10,000 H2 
sequences. 
Figure 2. CDR contact distribution and H2 contact profile. (A) Contacts reported in the international 
ImMunoGeneTics/3Dstructure-DB database. Contact as- signment is based on international ImMunoGeneTics’ 
definition of CDR positions. Data were obtained from 241 antibody-antigen cocrystal structures. (B) Position-
dependent contact distribution in H2. Valleys represent amino acids more likely to play a role in framework 
stability.  
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Finally, all CDR sequences were passed through a series of three filters to maximize their 
utility. First, all restriction sites to be used during library construction were eliminated by 
introducing silent codon changes. Second, we sought to minimize the potential immunogenicity 
of the scFvs by discarding peptides with a high potential for loading onto HLA class II molecules 
during antigen presentation. We used the ProPred online server to filter our CDR sequences 
against the four most common HLA-DRB1 alleles (101, 301, 701, and 1501) with a stringency of 
45% of the best substrate (43). This process resulted in replacement of about 18% of all H3 
sequences by less immunogenic peptides. The third filter replaced sequences with the potential to 
interfere with industrial scale production (e.g., methionine oxidation, asparagine 
deamidation/cyclization), as well as glycosylation motifs. 
The final set of 43,803 CDR sequences (L3, H2, H3L, H3R) were flanked by the 
appropriate restriction site sequences, as well as sublibrary-specific PCR primer binding 
sequences, and then synthesized as releasable oligonucleotides on a silicon wafer (Agilent 
Technologies). The oligo libraries were PCR-amplified and separately cloned into the VH1–69 
and VL1–44 human heavy- and light-chain variable fragments for combinatorial assembly 
(Figure 1D and Methods). In vitro transcription was then performed to create the mRNA 
templates for ribosome display. 
We characterized the HMM scFv library in two ways. First, we cloned a small sample of 
the library mRNA. This process allowed us to perform Sanger sequencing on individual 
colonies, and thereby estimate the overall fraction of the library expected to contain functional, 
full-length scFvs with no frameshift or nonsense mutations (57% functional, n = 93) (Figure 1E). 
None of the colonies examined had retained their CDR “suicide insert,” and none had multiple 
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CDR insertions. We found that the 43% nonfunctional clones derived mostly from oligo 
synthesis errors; ∼15% of each CDR was nonfunctional, resulting in 39% (1–0.853) 
nonfunctional clones. Second, we used our Illumina sequencing data to characterize the length 
distribution of the H3 loop (Figure 3). Satisfied that our library was true to its design, we next 
performed selections against the cancer antigen PVRL4 (44, 45), and used Illumina sequencing 
to track the library during selection.  
Selection(and(Analysis(of(HMM(scFv(Libraries(on(GST;PVRL4(Bait(
Figure 3. Length distribution of the H3 CDR library. Target H3 length distribution is based on the high-
throughput sequencing of an individual’s heavy-chain repertoire. Expected distribution is the calculated fraction of 
each length based on random ligation of all H3L sequences with all H3R sequences. The observed distribution is 
based on the analysis of the Illumina sequencing data from the unselected HMM scFv library.  
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Four successive rounds of selection were performed with the HMM scFv library on GST-
PVRL4. We quantified both enrichment of a spiked-in control scFv and the amount of RNA 
degradation during each round of selection to ensure these parameters met our quality-control 
thresholds (see Methods). After three selection rounds, the library was split and selected on either 
GST-PVRL4 or GST-GCN4 (no PVRL4) in parallel, which allowed us to discriminate between 
PVRL4-specific scFvs and those that bind to GST or to some other component of the system. 
The minimal region of the HMM scFvs that contains the three diversified CDRs is an 
appropriate size for analysis by paired-end Illumina sequencing. The sequencing libraries can 
thus be prepared conveniently by PCR. A small amount of each of the selected libraries, as well 
as the unselected HMM scFv library was amplified with Illumina sequencing adapters. These 
adapters include a 7-nt barcode to permit multiplexed analysis. 
We performed paired-end sequencing in two separate Illumina HiSeq 2000 flow cell 
lanes. By obtaining L3-H3 mate pairs in one lane and H2-H3 mate pairs in the other lane, we 
could use the hyperdiversity of H3 sequences to match corresponding L3 and H2 sequences, 
thereby reconstructing the complete identity of each scFv clone (Figure 4). After PCR 
amplification, however, we observed significant PCR chimerism, essentially resulting in CDR 
recombination. This complicated—but in most cases did not prevent—reconstruction of 
individual scFv clones. CDR recombination has been observed to significantly increase scFv 
affinity during ribosome display selection, suggesting that this process might actually improve 
the success rate of our platform (46).  
We next determined the relative abundance of each clone in the library over the course of 
four rounds of selection on GST-PVRL4, and compared this to the results from the round 3 
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PVRL4-selected library that was selected on GST-GCN4 (Figure 5). Based on this analysis, a 
subset of the candidate PVRL4-specific clones was selected for further analysis. 
Recovery(and(Testing(of(Candidate(Anti;PVRL4(HMM(scFvs(
Before characterizing individual scFvs for their ability to bind antigen, they must first be 
isolated. This isolation can be accomplished either by resynthesizing the CDRs for cloning back 
Figure 4. Strategy for sequence reconstruction of HMM scFv clones. One-hundred nucleotide paired-end 
sequencing is performed on the same library in two independent lanes on an Illumina HiSeq 2000. In the L3-H3 
lane, the first sequencing primer lands upstream of L3 (red “1” arrow). In the H2-H3 lane, the first sequencing 
primer lands upstream of H2 (red “1” arrow). The H3 sequence is then determined by reading from a common, 
second primer (red “2” arrow) in both lanes. L3 and H2 sequences are then paired using their unique H3 identifier 
to fully define the sequence of the scFv clone. 
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Figure 5. Fractional abundance of top 30 PVRL4-specific HMM scFv clones during selection. (A) The fractional 
abundance of the top 30 PVRL4-specific HMM scFv clones shown over four rounds of enrichment on GST-PVRL4. 
Fraction is calculated as read number of a clone divided by the total number of reads from the corresponding library. 
(B) The fractional abundance of the same 30 PVRL4-specific HMM scFv clones from A. Data from rounds R1–R3 
are the same in the two panels. Round 4 selection on the non-PVRL4 bait, GST-GCN4, results in a relative depletion 
of these clones from the population. 
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Figure 6. HMM scFv recovery strategy and FACS staining. (A) Candidate HMM scFv clones are recovered by 
PCR using primers specific for L3 and H3, and which also have 5′ homology arms for subsequent isothermal 
assembly into an expression vector with differing codon use. (B) Results of FACS staining to assess binding of 
candidate scFvs. HMECs infected with vector alone or vector-expressing PVRL4 antigen were stained with the 
indicated control antibodies or one of the top four most abundant postselection HMM scFv clones. 
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into an expression framework, or by PCR-recovering the clones using primers specific for L3 
and H3. We chose to recover candidate scFvs by performing PCR with L3/H3-specific primers 
that also contained 5′ homology arms for subsequent isothermal assembly into a FLAG/6His 
epitope-tag expression vector (Error! Reference source not found.A). Recovered candidate 
anti-PVRL4 scFv clones were expressed in vitro as FLAG-tagged proteins. Of the top 25 most 
abundant postselection clones, four were found to specifically bind human mammary epithelial 
cell (HMEC)-expressed PVRL4 by FACS-staining analysis (Figure 6B). The success rate of our 
method is likely underestimated by this analysis, however, as the selection bait was a bacterially-
produced, unmodified GST-PVRL4 fusion, whereas HMECs display the glycosylated protein in 
the context of the cell surface. 
Discussion(
Synthetic biology has yet to deliver antibody production platforms that rival vertebrate 
immune systems in both product quality and manufacturing convenience (47). However, we 
anticipate that along with the maturation of gene-synthesis technologies and the affordability of 
high-throughput DNA sequencing will also come advances in antibody production pipelines that 
outperform animal immune systems in all regards (48). 
To address the emerging need for a next-generation scFv production platform compatible 
with sequencing-assisted selection, we have created a rationally designed, single-framework 
scFv library. Single frameworks enable facile library amplification and sequencing using a single 
set of primers, but reduce framework-contributed functional diversity. To compensate for this 
potential loss of functionality, we used a mathematical model of structural data to capture subtle 
amino acid sequence biases that contribute to the formation of favorable antibody–antigen 
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contacts. We additionally developed a method to mimic the junctional diversity of VJ 
recombination using type IIS restriction cleavage followed by shuffling ligation. Our 
combinatorial strategy significantly reduces the required size of each CDR sublibrary, making 
extreme diversification of the final scFv library a tractable problem. Finally, to accomplish the 
analysis of selected scFv libraries using short-read DNA sequencing, we have introduced a 
strategy for double mate pair-based reconstruction of full-length scFv clones. 
One benefit of the three-CDR library presented here is the ease of clonal sequence 
reconstruction. We found that the hyperdiversity of our H3 CDR library permitted the near 
unambiguous pairing of L3 and H2 sequences with their shared H3, thus completely defining the 
repertoire at each round of selection. We went on to demonstrate an important advantage of 
single-framework libraries, which is the relative simplicity of recovering desirable clones. Our 
two-step protocol enables rapid isolation and assembly of clones into an expression vector for 
further functional characterization. In contrast, native heavy- and light-chain framework libraries 
are currently intractable to analysis with short-read sequencing, and require many more steps for 
clonal isolation. Although not demonstrated here, an additional design feature built into our 
platform is the ability to perform straightforward total synthesis of desirable clones from 
synthetic DNA oligos or oligo pools (Figure 7). It is worth noting that the utility of the HMM 
library is not limited to the ribosome display format, and can be moved into traditional phage or 
yeast display vectors. Similarly, alternative heavy- and light-chain frameworks can be 
synthesized to house the HMM CDR libraries described in this work. 
An unrealized application of sequencing-assisted selection is the parallel production of 
antibody sets that target multiple antigens. For example, an “array” of antigens can be pooled in  
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different configurations, screened, and the resulting antibodies deconvoluted so that scFvs 
specific to a single antigen can be deduced (49, 50). This strategy can reduce the number of 
selections to the square root of the number of antigens. Future single-pot, massively parallel 
selections will require the development of robust library-vs.-library deconvolution strategies, and 
preliminary progress has recently been reported (51). 
Figure 7. Total synthesis of HMM scFv clones. Strategy for reconstruction of desirable HMM scFv clones from synthetic 
oligos. After PCR amplification of the oligo or oligo library, the CDRs are assembled into an intermediate expression vector. 
The constant sequences of the framework regions between L3 and H2 (green) and between H2 and H3 (purple) are then 
sequentially inserted to form the complete HMM scFv expression clone or clone set. 
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As more sophisticated selection/deconvolution strategies emerge, and as immuno-PCR 
applications become more commonplace, we anticipate an increasing demand for efficient, low-
cost production of high-quality synthetic antibody reagents. The methods presented here are a 
step toward this goal. As a first iteration, however, our platform is not without limitations. For 
example, not all of the scFvs predicted to bind PVRL4 were found to do so by FACS analysis. 
Indeed this finding could reflect the different antigenic context of cell surface PVRL4 or it could 
be the result of inaccurate scFv clone-enrichment quantification. Advances in DNA sequencing 
depth and read length will improve our ability to quantify clonal abundances, and will eliminate 
the need for the double mate-pair reconstruction of full-length sequences presented here. Read-
length improvement will also facilitate analysis of libraries based on diversification of greater 
than three CDRs. 
For this proof-of-principle work, we did not incorporate mutagenic PCR into the library-
recovery protocol because it adds a layer of complexity to the analysis of enriched populations. 
However, the power of deep sequencing to map binding energy landscapes is now being realized 
(52) and will undoubtedly yield similar utility in the context of antibody selections. Finally, the 
profusion of additional antibody–antigen cocrystal structures will improve our ability to model 
CDR sequence biases that give rise to favorable antibody properties. With these considerations in 
mind, there is little doubt that sequencing-assisted selection of synthetic antibody libraries will 
play an increasingly important role in a wide variety of future biomolecular investigations. 
Methods(
HMM(scFv(Library(Assembly(
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We wished to use the J chains most commonly associated with the VH1–69 and VL1–44 
segments. In a sequenced heavy-chain repertoire from an individual, IGHJ4 was the J chain most 
often recombined with VH1–69. We used work by Schofield et al. to determine that in a large 
pool of selected phage, IGLJ2 was the J chain that most often recombined with VL1–44 (53). 
These components were assembled and reverse translated into an E. coli codon preference (Table 
1). We introduced silent mutations into the framework regions flanking L3, H2, and H3, for the 
purpose of cloning in the CDR libraries. We required that at least one of each of these pairs be 
nonpalindromic so as to minimize multiple CDR insertions during library cloning. To this end, 
we introduced a BbsI site 5′ and an Acc65I site 3′ of L3, a PflMI site 5′ and an ApoI site 3′ of 
H2, an AccI site 5′ and a BstEII site 3′ of H3. These pairs of cloning sites flanked replaceable 
suicide inserts, which contain a stop codon in all reading frames and a XhoI restriction site. The 
CDR libraries were released from the microarray as 10 pmol of single-stranded DNA and 
resuspended in 200 µL water. Next, 1 µL of each sublibrary was used as input for library-specific 
PCR using 1 µL Taq polymerase (TaKaRa) according to the manufacturer’s instructions (2 µM 
each primer). The thermal profile was: (i) 95 °C 5 m, [(ii) 94 °C 15 s, (iii) 55 °C 30 s, (iv) 68 °C 
15 s] × 24. At this point, the reaction was divided in two and primers were replenished. The 
thermal profile was then: (i) 95 °C 5 m, (ii) 94 °C 45 s, (iii) 67 °C 7 m. 
The L3 sublibrary was cloned into the scFv vector at the BbsI and Acc65I sites, 
electrotransformed into DH10B cells, and grown overnight on 15-cm carbenicillin plates. We 
harvested >107 transformants by scraping, and purified their plasmid DNA. Starting with this 
HMMscFv-L3 library, the same procedure was then used to replace the H2 suicide insert with 
the H2 library PCR product by using the engineered PflMI and ApoI sites. We obtained >107 
transformants (HMMscFv-L3-H2 library) and purified the plasmid DNA. The H3L library PCR  
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product was first NheI/BssHII subcloned into the pPAO2 vector (54). About 5 × 106 
transformants were obtained and plasmid DNA collected. In parallel, H3R library PCR product 
was prepared. From the pPAO2-H3L plasmid pool, ∼300 bp of upstream sequence was PCR-
amplified for subsequent size discrimination of H3L-H3R ligation product. Both pPAO2-H3L 
and H3R PCR products were digested with SapI for subsequent combinatorial ligation by their 5′ 
overhanging codons. High-concentration T4 ligation was carried out at 15 °C overnight, a 
condition that permits mismatched ligation at a relatively high frequency. Indeed, upon 
sequencing a large number of H3 clones, we observed many examples of library members with 
unmatched codons that were ligated together, and importantly, without disrupting the reading 
frame. After H3 ligation, the correct size product was gel-purified and PCR-amplified. This PCR 
product and the HMM scFv vector were then digested with AccI and BstEII, so that the final H3 
library could replace the vector’s H3 suicide insert. If only complementary codons were able to 
Table 1 
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ligate together, the theoretical diversity of the H3 sublibrary would be 1.2 × 107. However, we 
frequently observed noncomplementary ligation, thus increasing the expected diversity of H3. 
About 107 H3 clones were obtained. 
To bring together HMMscFv-L3-H2 and HMMscFv-H3 in a final ligation (Figure 1D), 
60 µg of each of library was first digested with AccI and BbsI and the desired fragment gel-
purified. In a high-concentration T4 ligation at 37 °C, the two fragments were ligated to form 
concatamers. Finally, the product was digested with both NotI (to release the desired in vitro 
transcription template) and XhoI (to destroy clones retaining a suicide insert) and gel-purified. 
We recovered 2.44 µg of HMMscFv-L3-H2-H3 library DNA at the correct size, which 
corresponds to 3.07 pmol or 1.85 × 1012, theoretically unique DNA molecules. This material was 
used as a template for in vitro transcription (RiboMAX Large Scale RNA Production System T7; 
Promega) to produce mRNA, which was subsequently isolated with TRI reagent (Ambion). 
Ribosome(Display(
Before immobilization of antigen-GST fusion protein, MagneGST beads (Promega) were 
washed 3× in 1× TBST. Five-microliter beads were used per immunoprecipitation, and beads 
were coated with 100 µL of bacterial lysate containing GST fusion protein mixed 1:1 with 
TBST. Two µL of 1M dTT were included. Binding occurred overnight by rotating at 4°C. RD 
Buffer, 1 L: 50 mM Tris Acetate (6.07 g), 150 mM NaCl (8.77 g), pH to 7.5 with acetic acid; 
autoclaved. Beads were washed 5× with buffer “RDWB+T” (RD Buffer plus 50 mM Mg Acetate 
and 0.5% Tween 20) and tubes were changed after every other wash. Beads were blocked in 50 
µL “Selection Buffer” (RDWB+T plus 2.5 mg/mL heparin and 1% BSA and 83.3 µg/mL tRNA) 
plus 1 µL RNasin (Promega) at 4 °C for 2 h. 
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Next, 6.37 µg RNA (1 × 1013 RNA molecules) per 14 L translation reaction were used. 
Translations were performed using the RTS 100 E. coli Disulfide kit (5 PRIME) according the 
manufacturer’s instructions, except that the feeding solution was not used. Translation was 
allowed to proceed for 13 min 45 s at 30 °C. Each 14 L reaction was immediately diluted with 
96 µL ice-cold Selection Buffer and 3 µL RNasin. Reactions were centrifuged 14,000 × g for 5 
min at 4 °C. Supernatant was then moved to a new, cold tube. Fifty-microliter beads in Selection 
Buffer was added to the ribosome-displayed HMM scFv library and rotated 4 h at 4°C. Beads 
were washed six times with 500 µL ice-cold RDWB+T. Tubes were changed after every other 
wash. Ribosomal complexes were disrupted after the final wash by resuspending beads in 50 µL 
“EB20” (RD Buffer plus 20 mM EDTA) plus 1 µL RNasin and incubated at 37°C for 10 min. 
Released RNA was then purified on Qiagen RNeasy column and eluted into 33 µL nuclease-free 
H2O. 
Superscript III kit (Invitrogen) was used to reverse transcribe the selected RNA library 
from the preTolA primer. Next, 1 µL (5 U) of E. coli RNase H (New England Biolabs) was 
incubated with the RT product at 37°C for 20 min. Recovered cDNA was first PCR-amplified 
using primers that flank an insert region containing the CDRs (LLF2 and LLR2). PCR 
amplification was performed with the GC-RICH PCR kit (Roche) using the following the 
conditions: 1× GC-RICH Buffer, 0.2 mM of dNTP, 0.2 µM LLF2 primer, 0.2 µM of LLR2 
primer, 0.5 µM of Resolution Solution, 1 µL of enzyme per 50 µL reaction. The thermal profile 
was: (i) 95°C for 3 min, [(ii) 95°C for 15 s, (iii) 55°C for 30 s, (iv) 72°C for 1 min] × 40 cycles, 
(v) 72°C for 7 min. The resulting PCR product was then double-digested with BbsI and BamHI 
(New England Biolabs), gel-extracted, and ligated using T4 Ligase into the pRDscFv2 vector. 
The ligation product was then PCR amplified using primers specific for the T7 promoter and the 
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TolA linker (T7B2 and TolA). PCR amplification was performed as above but with the T7B2 
and TolA primers. The final PCR product was digested with XhoI (New England Biolabs) and 
gel-purified for either Illumina sequencing or use in a subsequent round of selection. 
Recovery(of(HMM(scFv(Clones(from(a(Selected(Library(
Single HMM scFv clones were recovered from the selected library by PCR with CDR-
specific primers followed by assembly into a protein expression vector. Forward and reverse 
primers were designed to amplify target clone’s L3-H2-H3 insert and contained a 20 bp adapter 
sequence for assembly into the protein expression vector. PCR amplification was performed with 
the following conditions: 1× Phusion High-Fidelity PCR Master Mix with HF Buffer, 0.2 µM 
each of the forward and reverse primers, 1 µL of cDNA recovered after library selection per 50-
µL reaction. The thermal profile was: (i) 98°C for 30 s, [(ii) 98°C for 10 s, (iii) 72°C for 1 min] × 
30 cycles, (iv) 72°C for 10 min. 
PCR products were subsequently gel-purified and assembled into a protein expression 
vector using an isothermal assembly method. The protein expression vector contains the scFv 
framework followed by a FLAG tag and two in-frame stop codons. The isothermal assembly 
reaction was performed as previously described (55). Each reaction contained 100 ng of linear 
vector DNA lacking the L3-H2-H3 insert and 20 ng of the recovery PCR product, and was 
incubated at 50°C for 1 h. One-microliter of the assembly reaction product was transformed into 
DH5α E. coli cells and colonies were picked for sequence verification. Plasmids were expressed 
using the RTS 100 Disulfide Kit (5 PRIME) according the manufacturer’s instructions, except 
that the feeding solution was not used. The resulting product was used directly in subsequent 
experiments. 
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Construction(of(the(Ribosome(Display(Vector((
Plückthun and colleagues have optimized vectors capable of displaying single-chain 
variable fragments (scFvs) on ribosomes (56, 57). We adapted components of these and other 
such vectors to our present purpose. Beginning from the 5′ end of the DNA vector, the following 
parts were assembled as a synthetic gene product (DNA2.0):  
1.! T7 promoter for in vitro transcription from the DNA library 
(TAATACGACTCACTATAGGGAGACCACAACGGTTTCCC);  
2.! 5′ mRNA stemloop (5′-GGGAGACCACAACGGTTTCCC-3′) to improve transcript 
stability; 
3.! Ribosome binding site for translation of the library;  
4.! Kozak sequence for potential use in eukaryotic translation systems; 
5.! N-terminal 6xHis tag for detection and potential purification of scFv protein; 
6.! The variable domain of the light chain was encoded N-terminal to the heavy chain so that 
PCR recovery of the three diversified complementarity-determining regions (CDRs) (L3, 
H2, H3) would require the shortest amplicon;  
7.! Between the N-terminal variable light chain (VL) and C-terminal variable heavy chain 
(VH) is a “(G4S)3” linker with optimized codon use (5′-
ggtggtggtggtggttctggtggtggtggttctggcggcggcggctccagtggtggtggatcc-3′);  
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8.! The C terminus of VH is fused to a linker segment derived from the TolA Escherichia 
coli protein (accession: NP_415267, position 131–214), which provides a spacer between 
the displayed scFv and the ribosomal tunnel;  
9.! 3′ mRNA stemloop (5′-CCGCACACCTTACTGGTGTGCGG-3′) to improve transcript 
stability.  
NotI sites flank the 3′ and 5′ ends of the construct for isolation of the in vitro transcription 
template. Directional SfiI sites flank the minimal scFv for facile movement of clones into and out 
of alternative expression vectors. 
Quality(Control(During(scFv(Selection((
We used a positive control scFv and bait pair to optimize our ribosome display selection 
protocol. Pluckthun and colleagues have used ribosome display to affinity mature an scFv 
(4c11L34Ser, “Pluck-scFv”) to high affinity (Kd = 40 pM) for a peptide derived from the yeast 
GCN4 protein (58). Our eventual goal was to perform selections on GST-fusion proteins, and so 
we expressed GST-GCN4 in BL21 E. coli cells as a positive-control bait. As a negative-control 
scFv, a random clone (“rand-scFv”) was picked from a naive human repertoire (59) and 
expressed in the same ribosome display vector backbone. A negative-control peptide, “GST-pep” 
was used as nonspecific bait. Protocol optimization experiments were undertaken to maximize 
the amount of both enrichment and recovery of the Pluck-scFv that be could be attained. For 
most experiments, Pluck-scFv was diluted 1,000-fold into a background of rand-scFv, and GST- 
GCN4 was diluted 1,000-fold into a background of GST-pep. Our selection protocol typically 
achieved enrichments of several hundred-fold, and recovery of ∼0.2%. This relatively low rate 
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of recovery is consistent with known inefficiencies inherent to the ribosome display technology 
(60).  
We incorporated a system of quality-control measures to en- sure the success of each 
round of hidden Markov model (HMM) scFv library selection. First, we spiked Pluck-scFv into 
our HMM scFv library and GST-GCN4 into our selection bait (GST- PVRL4), both at a dilution 
of 1:1,000. In this way, the efficiency of enrichment and recovery for each selection could be 
quantitatively monitored using a probe specific for the Pluck-scFv control. If enrichment or 
recovery of Pluck-scFv was below a threshold, then the selection was considered a failure and 
repeated. For our selections, we required enrichment of Pluck-scFv to be at least 50- fold and the 
recovery of Pluck-scFv be at least 0.04%. Second, degradation of mRNA transcripts is a concern 
with ribosome display, and so we used TaqMan probes targeting the constant 3′ and 5′ ends of 
the scFv transcript. In the absence of mRNA degradation, these two signals arise with equal 
strength. The distal, 5′ signal is differentially diminished by degradation, and so the ratio of the 
two signals can be used to measure the amount of degradation that occurred during the selection. 
If the ratio of the 5′ signal to the 3′ signal was below our threshold of 1:5, the selection was 
considered a failure and repeated.  
Illumina(Sequencing(
Libraries for Illumina sequencing were pre- pared by two rounds of PCR amplification to 
add the Illumina adapters and barcode sequences. Libraries were PCR-amplified from the in vitro 
transcription template DNA using the TaKaRa EX HS kit (Clontech). The conditions for the first 
round of PCR were: 1× TaKaRa EX HS Buffer, 0.2 mM dNTP, 0.4 µM IS7_L3F_PE primer, 0.4 
µM IS8_H3R_PE_Multi primer, 0.5 µL TaKaRa Ex HS enzyme, and 1 µL of template per 50-µL 
reaction. The thermal profile was: [(i) 98°C for 10 s, (ii) 50°C for 30 s, (iii) 72°C for 1 min 30 s] 
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× 10 cycles, (iv) 72°C for 7 min. The conditions for the second round of PCR were: 1× TaKaRa 
EX HS Buffer, 0.2 mM dNTP, 0.5 µM of IS4_L3F_PE primer, 0.5 µM of the barcoding primer, 
0.5 µL TaKaRa Ex HS enzyme, and 1 µL of the first round PCR product per 50-µL reaction. The 
thermal profile was: [(i) 98 °C for 10 s, (ii) 60 °C for 30 s, (iii) 72 °C for 1 min 30 s] × 10 cycles, 
(iv) 72 °C for 7 min.  
As the complexity of the libraries is expected to decrease significantly with each round of 
selection, we divided the contribution of each library by two for each round of enrichment 
undergone. For example, if we added 100 ng of input library product to the multiplex pool, then 
we would add 50 ng of round 1 selected library, 25 ng of round 2 selected library, 12.5 ng of 
round 3 selected library, and so on. All second-round PCR products were gel-purified before 
sequencing on an Illumina HiSeq 2000 instrument.  
Analysis(of(High;Throughput(Sequencing(Results((
All reads were separated into samples according to the barcode sequence by the standard 
Illumina software. Framework sequences were trimmed according to the following rules: L3 and 
H2 reads were truncated to their respective lengths (36 nt and 39 nt, respectively). H3 reads were 
trimmed of 5′ and 3′ framework sequences with an error rate of 0.2 using cutadapt (61). Reads 
were then aligned to con- sensus sequences with up to two mismatches using bowtie software 
(62): First, all of the reads in a sample were tallied and an index was built for each sample. 
Second, each read in a sample was aligned globally against that sample’s index with up to two 
mismatches allowed. The alignment with the highest tally (i.e., the read that occurred most 
frequently in that sample) was chosen as the consensus sequence for that read. Finally, reads that 
contain wildcards (“N”) or stop codons were discarded. The paired L3-H3 or H2-H3 reads were 
then joined and the fre- quency of unique pairs was tallied. For paired L3-H3, we obtained 2.58 × 
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107, 2.12 × 107, 9.82 × 106, 1.08 × 106, 5.19 × 105, and 5.33 × 105 total reads for the input 
library, round 1, round 2, round 3, round 4, and GCN4 selections, respectively. After applying 
our filtering algorithm, we obtained 1.60 × 107, 1.97 × 107, 8.66 × 106, 8.77 × 105, 4.71 × 105, 
and 4.97 × 105 reads, respectively. For paired H2-H3, we obtained 2.02 × 107, 1.68 × 107, 7.55 × 
106, 8.08 × 105, 3.90 × 105, and 4.10 × 105 total reads for the input library, round 1, round 2, 
round 3, round 4, and GCN4 selections, respectively. After applying our filtering algorithm, we 
obtained 1.89 × 107, 7.16 × 106, 6.71 × 106, 6.72 × 105, 3.55 × 105, and 2.94 × 105 reads, 
respectively. After four rounds of selection the median read depth of the top 10 L3-H3 paired 
clones was 55.5 and the median read depth of the top 10 H2-H3 paired clones was 289.5. In each 
of the libraries, there is a long tail of clones that are sequenced only once.  
Live;Cell(FACS(Analysis((
Telomerase-large T-antigen–immortalized human mammary epithelial cells (TL-
HMECs) were transduced with retroviral constructs expressing human PVRL4 or control (empty 
vector). For labeling with in vitro-translated scFvs, cells were dissociated from the tissue-culture 
plate with enzyme-free cell dissociation buffer (Invitrogen), resuspended in Stain buffer (BD 
Biosciences), and filtered through a 35-µm nylon mesh cell strainer (BD Biosciences). Cells 
were incubated with in vitro- translated FLAG-tagged scFvs at a 1:100 dilution or anti-PVRL4 
mouse monoclonal antibody (R&D Systems) for 30 min on ice, washed twice with Stain buffer, 
and incubated with M2 anti- FLAG antibody (Sigma) at a 1:100 dilution for 30 min on ice. 
Labeled cells were washed twice and incubated with Alexa Fluor 488-conjugated goat–anti-
mouse secondary antibody (Invitrogen) at 1:500 dilution for 30 min on ice. After a final series of 
washes, cells were resuspended in Stain buffer. Fluorescent signal was measured on LSR II 
FACS Analyzer (BD Bio- sciences) and analyzed with FlowJo software.  
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Abstract(
The human virome plays important roles in health and immunity. However, current 
methods for detecting viral infections and antiviral responses have limited throughput and 
coverage. Here, we present VirScan, a high-throughput method to comprehensively analyze 
antiviral antibodies using immunoprecipitation and massively parallel DNA sequencing of a 
bacteriophage library displaying proteome-wide peptides from all human viruses. We assayed 
over 108 antibody-peptide interactions in 569 humans across four continents, nearly doubling the 
number of previously established viral epitopes. We detected antibodies to an average of 10 viral 
species per person and 84 species in at least two individuals. Although rates of specific virus 
exposure were heterogeneous across populations, antibody responses targeted strikingly 
conserved “public epitopes” for each virus, suggesting that they may elicit highly similar 
antibodies. VirScan is a powerful approach for studying interactions between the virome and the 
immune system. 
Introduction(
The collection of viruses found to infect humans (the "human virome”) can have 
profound effects on human health (63). In addition to directly causing acute or chronic illness, 
viral infection can also alter host immunity in more subtle ways, leaving an indelible footprint on 
the immune system (64). For example, latent herpesvirus infection has been shown to confer 
symbiotic protection against bacterial infection in mice through prolonged production of 
interferon-γ and systemic activation of macrophages (65). This interplay between virome and 
host immunity has also been implicated in the pathogenesis of complex diseases such as type 1 
diabetes, inflammatory bowel disease, and asthma (66). Despite this growing appreciation for the 
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importance of interactions between the virome and host, a comprehensive method to 
systematically characterize these interactions has yet to be developed (67). 
Viral infections can be detected by serological- or nucleic acid-based methods (68). 
However, nucleic acid tests fail in cases where viruses have already been cleared after causing or 
initiating tissue damage and can miss viruses of low abundance or viruses not normally present 
in the sampled fluid or surface. In contrast, humoral responses to infection typically arise within 
two weeks of initial exposure and can persist over years or decades (21). Tests detecting antiviral 
antibodies in peripheral blood can therefore identify ongoing and cleared infections. However, 
current serological methods are predominantly limited to testing one virus at a time and are 
therefore only employed to address specific clinical hypotheses. Scaling serological analyses to 
encompass the complete human virome poses significant technical challenges, but would be of 
great value for better understanding host-virus interactions, and would overcome many of the 
limitations associated with current clinical technologies. In this work, we present VirScan, a 
programmable, high-throughput method to comprehensively analyze antiviral antibodies using 
immunoprecipitation and massively parallel DNA sequencing of a bacteriophage library 
displaying proteome-wide coverage of peptides from all human viruses. 
Results(
The(VirScan(platform(
VirScan utilizes the Phage Immunoprecipitation sequencing (PhIP-seq) technology 
previously developed in our laboratory (19). Briefly, we used a programmable DNA microarray 
to synthesize 93,904 200-mer oligonucleotides, encoding 56-residue peptide tiles, with 28 
residue overlaps, that together span the reference protein sequences (collapsed to 90% identity) 
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of all viruses annotated to have human tropism in the UniProt database (Figure 8a and b) (69). 
This library includes peptides from 206 species of virus and over 1,000 different strains. We 
cloned the library into a T7 bacteriophage display vector for screening (Figure 8c).  
 
To perform a screen, we incubate the library with a serum sample containing antibodies, 
recover the antibodies using a mixture of protein A and G coated magnetic beads, and remove 
unbound phage particles by washing (Figure 8d and e). Finally, we perform PCR and massively 
parallel sequencing on the phage DNA to quantify enrichment of each library member due to 
antibody binding (Figure 8f). Each sample is screened in duplicate to ensure reproducibility. 
Figure 8. Construction of the virome peptide library and VirScan screening procedure. (a) The virome peptide 
library consists of 93,904 56 amino acid peptides tiling, with 28 amino acid overlap, across the proteomes of all 
known human viruses. (b) 200 nt DNA sequences encoding the peptides were printed on a releasable DNA 
microarray. (c) The released DNA was amplified and cloned into a T7 phage display vector and packaged into virus 
particles displaying the encoded peptide on its surface. (d) The library is mixed with a sample containing antibodies 
that bind to their cognate peptide antigen on the phage surface. (e) The antibodies are immobilized and unbound 
phage are washed away. (f) Finally, amplification of the bound DNA and high throughput sequencing of the insert 
DNA from bound phage reveals peptides targeted by sample antibodies. Abbreviations: aa, amino acid; Ab, 
antibody; IP: immunoprecipitation. 
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VirScan requires only 2 µg of immunoglobulin (<1 µL of serum) per sample and can be 
automated on a 96-well liquid handling robot (70). PCR product from 96 immunoprecipitations 
can be individually barcoded and pooled for sequencing, reducing the cost for a comprehensive 
viral antibody screen to approximately $25 per sample.  
Following sequencing, we tally the read count for each peptide before (“input”) and after 
(“output”) immunoprecipitation. We then fit a zero-inflated generalized Poisson model to the 
distribution of output read counts for each input read count and regress the parameters as a 
function of input read count (Figure 9).  
Using this model, we calculate a -log10(p-value) for the significance of each peptide’s 
enrichment. Finally, we call a peptide significantly enriched if its -log10(p-value) is greater than 
the reproducibility threshold of 2.3 in both replicates (Figure 10). 
Figure 9. Zero inflated generalized poisson (ZIGP) parameters regressed on input count. Each scatter plot depicts 
the maximum likelihood estimates for the ZIGP parameters as a function of the input count (horizontal axis; see 
Materials and Methods). Dashed lines are least-squares linear regressions for θ and λ, and least-squares exponential 
regression for π. 
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Figure 10. Reproducibility threshold. Scatterplot for median and median absolute deviation of replicate 2 -log10(p-
values) whose replicate 1 -log10(p-value) falls within the window whose left edge is shown on the horizontal axis 
(see Materials and Methods). 
Characterizing(VirScan’s(sensitivity(and(specificity(
Figure 11 shows the antibody profiles of a set of human viruses in sera from a typical 
group of individuals in a heat map format that illustrates the number of enriched peptides from 
each virus. We frequently detected antibodies to multiple peptides from common human viruses, 
such as Epstein-Barr virus (EBV), Cytomegalovirus (CMV), and rhinovirus. As expected, we 
observed more peptides to be enriched from viruses with larger proteomes, such as EBV and 
CMV, likely because there are more epitopes available for recognition. We noticed fewer 
enriched peptides in samples from individuals less than ten years of age compared to their 
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geographically matched controls, in line with an accumulation of viral infections throughout 
adolescence and adulthood. However, there were occasional samples from young donors with 
very strong responses to viruses that cause childhood illness, such as Parvovirus B19 and 
Herpesvirus 6B, which cause the “fifth disease” and “sixth disease” of the classical infectious 
childhood rashes, respectively (71). These observations are examined in greater detail in Figure 
15.  
We developed a computational method to identify the set of viruses to which an 
individual has been exposed, based on the number of enriched peptides identified per virus. 
Briefly, we set a threshold number of significant non-overlapping enriched peptides for each 
virus. We empirically determined that a threshold of three non-overlapping enriched peptides 
gave the best performance for detecting Herpes simplex virus 1 compared to a commercial 
serologic test, described below (Table 2). For other viruses, we adjusted the threshold to account 
for the size of the viral proteome (Figure 12). Next, we tally the number of enriched peptides 
from each virus. Antibodies generated against a specific virus can cross-react with similar 
Figure 11. Antibody profile of randomly chosen group of donors to show typical assay results. Each row is a virus, 
each column is a sample. The label above each chart indicates whether the donors are over 10 years of age or at most 
10 years of age. The color intensity of each cell indicates the number of peptides from the virus that were 
significantly enriched by antibodies in the sample. 
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peptides from a related virus. This would lead to false positives because an antibody targeted to 
an epitope from one virus to which a donor was exposed would also enrich a homologous 
peptide from a related virus to which the donor may not have been exposed. In order to address 
this issue, we adopted a maximum parsimony approach to infer the fewest number of virus 
exposures that could elicit the observed spectrum of antiviral peptide antibodies. For groups of 
enriched peptides that share a 7 amino acid subsequence and may be recognized by a single 
specific antibody, we only count it as one epitope for the virus that has the greatest number of 
other enriched peptides. If this adjusted peptide count is greater than the threshold for that virus, 
Figure 12. Correlation between virus size and number of enriched peptides. Each dot on this log-log scatterplot is 
a virus. The horizontal axis corresponds to the size of the virus in number of peptides. The vertical axis 
corresponds to the average number of peptides enriched from the virus across all samples tested. The dashed line is 
a least-squares best-fit curve for the data. 
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the sample is considered positive for the virus. For this analysis, we also filtered out peptides that 
were enriched in only one of the 569 samples to avoid spurious hits. 
Using this analytical framework, we measured the performance of VirScan using serum 
samples from patients known to be infected or not infected with human immunodeficiency virus 
(HIV) and Hepatitis C virus (HCV), based on commercial ELISA and Western blot assays. For 
both viruses, VirScan achieves very high sensitivities and specificities of ~95% or higher (Table 
2) over a wide range of viral loads (Figure 13). The viral genotype was also known for the HCV 
positive samples. Despite the over 70% amino acid sequence conservation among HCV 
genotypes (72), which poses a problem for all antibody-based detection methods, VirScan 
correctly reported the HCV genotype in 69% of the samples. We also compared VirScan to a 
commercially available serology test that is type specific for the highly related Herpes simplex 
viruses 1 and 2 (HSV1 and HSV2) (Table 1). These results demonstrate that VirScan performs 
well in distinguishing between closely related viruses and viruses that range in size from small 
(HIV and HCV) to very large (HSV1 and HSV2) with high sensitivity and specificity.  
Virus Sensitivity (n) Specificity (n) 
Hepatitis C virus 92% (26) * 97%
** (34) 
Human immunodeficiency virus 1 95% (61) * 100% (33) 
Herpes simplex virus 1 97% (38) 100% (6) 
Herpes simplex virus 2 90% (20) 100% (24) 
Table 2. Virscan’s sensitivity and specificity on samples with known viral infections. Sensitivity is the percentage 
of samples positive for the virus as determined by VirScan out of all n known positives. Specificity is the percentage 
of samples negative for the virus by VirScan out of all n known negatives. 
* We found that although the false negative samples did not meet our stringent cut-off for enriching multiple unique 
peptides, they had detectable antibodies to a recurrent epitope. By modifying the criterion to allow for samples that 
enrich multiple homologous peptides that share a recurrent epitope as described in the text, the sensitivity of 
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detecting Hepatitis C virus increases to 100% and the sensitivity for detecting HIV increases to 95%. This modified 
criterion does not significantly affect specificity (fig. S13). 
** The one false positive was from an individual whose HCV-negative status was self-reported, but had antibodies to 
as many HCV peptides as 23% of the true HCV positive individuals and is likely to be HCV positive now or in the 
past.  It is possible that this individual was exposed to HCV but cleared the infection. If true, the observed specificity 
for HCV is 100%. 
 
Figure 13. Scatter plot of the number of unique enriched peptides (after applying maximum parsimony filtering) 
detected in each sample against the viral load in that sample. Data are shown for the HCV positive and HIV positive 
samples for which we were able to obtain viral load data. For the HIV positive samples, red dots indicate samples 
from donors currently on highly active anti-retroviral therapy at the time the sample was taken, whereas blue dots 
indicate different donors prior to undergoing therapy. 
 52 
Population;level(analysis(of(viral(exposures(
After ascertaining the performance of VirScan for a panel of viruses, we undertook a 
large-scale screening of samples with unknown exposure history. Using our multiplex approach, 
we assayed over 106 million antibody-peptide interactions using samples from 569 human 
donors in duplicate. We detected antibody responses to an average of 10 species of virus per 
sample (Figure 14).  
 
Each person is likely exposed to multiple distinct strains of some viral species. We 
detected antibody responses to 62 of the 206 species of virus in our library in at least 5 
individuals, and 84 species in at least 2 individuals. The most frequently detected viruses are 
generally those known to commonly infect humans (Table 3). We occasionally detected what 
appear to be false positives that may be due to antibodies that cross react with non-viral peptides. 
For example, 29% of the samples positive for Cowpox virus were right at the threshold  
Figure 14. Distribution of number of viruses detected in each sample. The histogram depicts the 
frequency of samples binned by the number of virus species detected by VirScan. The mean and 
median of the distribution are both approximately 10 virus species. 
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Human herpesvirus 4 87.1% 98.5% 87.4% 1.4% 13 
Rhinovirus B 71.8% 52.7% 96.4% 5.0% 5 
Human adenovirus C 71.8% 80.2% 71.6% 0.8% 4 
Rhinovirus A 67.3% 59.1% 99.0% 4.6% 8 
Human respiratory syncytial virus 65.7% 67.0% 86.2% 5.7% 4 
Human herpesvirus 1 54.4% 87.5% 89.9% 1.1% 6 
Influenza A virus 53.4% 57.0% 55.2% 0.1% 1 
Human herpesvirus 6B 52.8% 66.3% 61.3% 0.7% 4 
Human herpesvirus 5 48.5% 96.7% 95.3% 0.9% 19 
Influenza B virus 40.5% 55.2% 51.2% 1.7% 4 
Poliovirus 33.7% 40.4% 81.7% 2.0% 2 
Human herpesvirus 3 24.3% 54.7% 77.3% 1.0% 4 
Human adenovirus F 20.4% 17.5% 81.0% 0.4% 3 
Human adenovirus B 16.8% 38.5% 71.2% 0.6% 3 
Human herpesvirus 2 15.5% 75.0% 85.4% 0.7% 6 
Enterovirus A 15.2% 12.8% 70.2% 2.3% 3 
Enterovirus B 13.3% 7.3% 95.1% 3.3% 5 
Mamastrovirus 1 9.4% 24.1% 55.2% 0.7% 2 
Human herpesvirus 7 9.1% 42.9% 92.9% 0.4% 4 
Norwalk virus 8.7% 25.9% 96.3% 1.2% 3 
Human adenovirus D 8.4% 38.5% 50.0% 0.4% 3 
Human parainfluenza virus 3 7.4% 21.7% 47.8% 1.6% 2 
Cowpox virus 7.1% 9.1% 36.4% 0.1% 1 
Human adenovirus A 6.5% 35.0% 55.0% 0.5% 2 
Human metapneumovirus 5.2% 43.8% 43.8% 2.8% 4 
Human coronavirus HKU1 4.5% 0.0% 42.9% 0.2% 3 
Human herpesvirus 6A 4.2% 30.8% 46.2% 0.4% 4 
Alphapapillomavirus 9 4.2% 30.8% 61.5% 0.5% 3 
Human parvovirus B19 3.9% 25.0% 75.0% 1.5% 3 
Aichivirus A 3.9% 33.3% 66.7% 2.6% 5 
Hepatitis B virus 3.6% 9.1% 18.2% 0.0% 0 
Betapapillomavirus 1 3.2% 0.0% 40.0% 0.1% 1 
Influenza C virus 2.9% 33.3% 55.6% 0.2% 2 
Human coronavirus NL63 2.9% 0.0% 55.6% 1.1% 3 
Human herpesvirus 8 2.6% 50.0% 50.0% 0.5% 4 
Rubella virus 2.6% 12.5% 50.0% 1.5% 2 
Human adenovirus E 2.3% 14.3% 71.4% 0.5% 1 
Hepatitis E virus 1.9% 0.0% 33.3% 0.4% 3 
Torque teno virus 1.6% 0.0% 60.0% 0.9% 3 
Hepatitis C virus 1.6% 80.0% 13.1% 0.0% 0 
Measles virus 1.6% 20.0% 80.0% 2.2% 3 
Alphapapillomavirus 10 1.6% 0.0% 80.0% 1.1% 3 
Human parainfluenza virus 4 1.6% 0.0% 80.0% 6.3% 3 
Eastern equine encephalitis virus 1.3% 0.0% 75.0% 0.7% 1 
Rotavirus A 1.3% 0.0% 50.0% 0.1% 1 
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Table 3. Detection frequency of all viruses detected in at least 4 (>1%) of the 303 donors residing in the United 
States. Known HIV-positive and HCV-positive samples were excluded from this analysis. The “Detection 
Frequency” column shows the percentage of the 303 US samples that were positive for each virus. Of the samples 
that are positive for each virus, the “Above Minimum Threshold” column shows the percentage that enriched more 
unique peptides than just the minimum threshold for that virus (Fig S3), and the “Most Recurrent Peptide” column 
shows the percentage that enriched the most recurrent peptide for that virus. The “Number Unique Peptides 
Recurrent” column shows the number of unique peptides (peptides that do contain the identical subsequences of 7 
amino acids or longer) from that virus that are enriched in at least 30% of the samples that are positive for that virus. 
The “Fraction Peptides Recurrent” column shows the total number of recurrent peptides from a virus divided by the 
number of all peptides from that virus. 
of detection and had antibodies against a peptide from the C4L gene that shares an eight amino 
acid sequence (‘SESDSDSD’) with the Clumping Factor B protein from Staphylococcus aureus, 
against which humans are known to generate antibodies (73). This will become less of an issue 
when we test more examples of sera from patients with known infections to determine the set of 
likely antigenic peptides for a given virus. However, the fact that we do not detect high rates of 
very rare or virulent viruses strengthens our confidence in VirScan’s specificity. 
We frequently detected antibodies to rhinovirus and respiratory syncytial virus, which are 
normally found only in the respiratory tract, indicating that VirScan using blood samples is still 
able to detect viruses that do not cause viremia. We also detected antibodies to influenza, which 
is normally cleared, and poliovirus, to which most people in modern times generate antibodies 
through vaccination. Since the original antigen is no longer present, we are likely detecting 
antibodies secreted by long-lived memory B cells (74).  
We detected antibodies to certain viruses less frequently than expected based on previous 
seroprevalence studies using optimized serum ELISA assays. For example, the frequency at 
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which we detect influenza (53.4%) and poliovirus (33.7%) is lower than expected given that the 
majority of the population has been exposed to or vaccinated against these viruses. This may be 
due to reduced sensitivity because of a gradual narrowing and decrease of the long-lived B cell 
response in the absence of persistent antigen. We also rarely detected antibody responses to 
small viruses such as JC virus and Torque Teno virus, which are frequently detected using 
specific tests. We believe that the disparity is due to low titers of antibodies to unmodified, linear 
epitopes from these viruses. For example, serum antibodies against the major capsid protein of 
JCV are reported to only recognize conformational epitopes (75). Finally, the frequency of 
detecting varicella zoster virus (chicken pox) antibodies is also lower than expected (24.3%), 
even though the frequency of detecting other latent herpesviruses, such as Epstein-Barr virus 
(87.1%) and cytomegalovirus (48.5%), is similar to the prevalence reported in epidemiological 
studies (76–78). This may reflect differences in how frequently these viruses shed antigens that 
stimulate B cell responses or a more limited humoral response that relies on epitopes that cannot 
be detected in a 56-residue peptide. It might also be possible to increase the sensitivity of 
detection of these viral antibodies by stimulating memory B cells in vitro to probe the history of 
infection more deeply. 
To assess differences in viral exposure between populations, we split the samples into 
different groups based on age, HIV status, and geography. We first compared results from 
children under the age of ten to adults within the United States (HIV-positive individuals were 
excluded from this analysis) (Figure 15A). Fewer children were positive for most viruses, 
including Epstein-Barr virus, HSV1, HSV2, and influenza virus, which is consistent with our 
preliminary observations comparing the number of enriched peptides (Figure 11). In addition to 
the fact that children may generate lower antibody titers in general, these younger donors
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probably have not yet been exposed to certain viruses, for example HSV2 which is sexually 
transmitted (79).  
When comparing results from HIV positive to HIV negative samples, we found more of 
the HIV positive samples to also be seropositive for additional viruses, including HSV2, CMV, 
and Kaposi’s sarcoma-associated herpesvirus (KSHV) (false discovery rate q < 0.05, Figure 
15B). These results are consistent with prior studies indicating higher risk of these co-infections 
in HIV positive patients (80–82). Patients with HIV may engage in activities that put them at 
Figure 15. Population stratification of the human virome immune response. The bar graphs depict the differences in 
exposure to viruses between donors who are (A) less than ten years of age versus over ten years of age, (B) HIV 
positive versus HIV negative, (C) residing in Peru versus residing in the United States, (D) residing in South Africa 
versus residing in the United States, and (E) residing in Thailand versus residing in the United States. Asterisks 
indicate false discovery rate < 0.05. 
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higher risk for exposure to these viruses. Alternatively, these viruses may increase the risk of 
HIV infection. HIV infection may reduce the immune system’s ability to control reactivation of 
normally dormant resident viruses or to prevent opportunistic infections from taking hold and 
triggering a strong adaptive immune response. 
Finally, we compared the evidence of viral exposure between samples taken from adult 
HIV-negative donors residing in countries from four different continents (the United States, 
Peru, Thailand, and South Africa). In general, donors outside the United States had higher 
frequencies of seropositivity (Figure 15C-E). For example, cytomegalovirus antibodies were 
found in significantly higher frequencies in samples from Peru, Thailand, and South Africa. 
Other viruses, such as Kaposi’s sarcoma-associated herpesvirus and HSV1 were detected more 
frequently in donors from Peru and South Africa, but not Thailand. The observed detection 
frequency of different adenovirus species varies across populations. Adenovirus C seropositivity 
was found at similar frequencies in all regions, but Adenovirus D seropositivity was generally 
higher outside the United States, while Adenovirus B seropositivity was higher in Peru and 
South Africa, but not in Thailand. The higher rates of virus exposure outside the United States 
could be due to differences in population density, cultural practices, sanitation, or genetic 
susceptibility. Interestingly, Influenza B seropositivity was more common in the United States 
compared to other countries, especially Peru and Thailand. The global incidence of Influenza B 
is much lower than Influenza A but the standard influenza vaccination contains both Influenza A 
and B strains, so the elevated frequency of individuals with seroreactivity may be due to higher 
rates of influenza vaccination in the United States. Other viruses, such as Rhinovirus and 
Epstein-Barr virus, were detected at very similar frequencies in all the geographic regions. 
 58 
Analysis(of(viral(epitope(determinants(
After analyzing responses on the whole virus level, we focused our attention on the 
specific peptides targeted by these antibodies. We detected antibodies to a total of 8,425 peptides 
in at least 2 samples, and 15,052 in at least 1 sample. Because of the presence of many related 
peptides in our library and the Immune Epitope Database (IEDB), for the following analysis we 
consider a peptide unique only if it does not contain a continuous 7-residue subsequence, the 
estimated size of a linear epitope, in common with another peptide. Analyzed as such, our 
VirScan database nearly doubles the 1,559 unique human B cell epitopes from human viruses in 
the IEDB (83). The epitopes identified in our unbiased analysis demonstrate a significant overlap 
with those contained in the IEDB (p < 10-30, Fisher’s exact text, Figure 16). The amount of 
overlap is even greater for epitopes from viruses that commonly cause infection. We would 
likely have detected even more antigenic peptides in common with the IEDB if we had tested 
more samples from individuals infected with rare viruses. We next analyzed the amino acid 
composition of recurrently enriched peptides. Enriched peptides tend to have more proline and 
charged amino acids and fewer hydrophobic amino acids, which is consistent with a previous 
analysis of B cell epitopes in the IEDB (Figure 17) (84). This trend likely reflects enrichment for 
amino acids that are surface exposed or can form stronger interactions with antibodies.  
B(cell(responses(target(highly(similar(viral(epitopes(across(individuals(
We compared the profile of peptides recognized by the antibody response in different 
individuals. We found that for a given protein, each sample generally only had strong responses 
against one to three immunodominant peptides (Figure 18). Surprisingly, we found that the vast   
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Figure 16. (Upper portion) Overlap between enriched peptides detected by VirScan and human B cell epitopes 
from viruses in IEDB. The entire pink circle represents the 1,392 groups of non-redundant IEDB epitopes that are 
also present in the VirScan library (out of 1,559 clusters total). The overlap region represents the number of groups 
with an epitope that is also contained in an enriched peptide detected by VirScan. The purple only region 
represents the number of non-redundant enriched peptides detected by VirScan that do not contain an IEDB 
epitope. Data are shown for peptides enriched in at least one (left) or at least two (right) samples. (Lower portion) 
Overlap between enriched peptides detected by VirScan and human B cell epitopes in IEDB from common human 
viruses. The regions represent the same values as the top except only epitopes corresponding to the indicated virus 
are considered, and only peptides from that virus that were enriched in at least two samples were considered. 
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Figure 17. Amino acid composition of enriched peptides. (A) Bar graph of the fractional abundance of 
each amino acid in the entire virome peptide library or peptides enriched in at least 2 samples. (B) Bar 
graph of the fractional abundance of each amino acid in peptides enriched in at least 2 samples subtracted 
by the abundance in the entire library. 
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Figure 18. The human anti-virome response recognizes a similar spectrum of peptides among infected individuals. 
In the heatmap charts, each row is a peptide tiling across the indicated protein and each column is a sample. The 
colored bar above each column, labeled at the top of the figure, indicates the country of origin for that sample. The 
samples shown are a subset of individuals with antibodies to at least one peptide from the protein. The color 
intensity of each cell corresponds to the -log10(p-value) measure of significance of enrichment for a peptide in a 
sample (greater values indicates stronger antibody response). Data are shown for (A) Human respiratory syncytial 
virus Attachment Glycoprotein G (G), (B) Human adenovirus C penton protein (L2), and (C) Epstein-Barr virus 
nuclear antigen 1 (EBNA1). Data shown are the mean of two replicates. 
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majority of seropositive samples for a given virus recognized the same immunodominant 
peptides, suggesting that the antiviral B cell response is highly stereotyped across individuals. 
For example, in glycoprotein G from respiratory syncytial virus, there is only a single 
immunodominant peptide comprising positions 141-196 that is targeted by all samples with 
detectable antibodies to the protein, regardless of the country of origin (Figure 18A).  
 For other antigens, we observed inter-population serological differences. For example, 
two overlapping peptides from position 309-364 and 337-392 of the penton base protein from 
Adenovirus C frequently elicited antibody responses (Figure 18B). However, donors from the 
United States and South Africa had much stronger responses to peptide 309-364 (p < 10-6, t-test) 
relative to donors from Thailand and Peru. We observed that for the EBNA1 protein from 
Epstein Barr virus, donors from all four countries frequently had strong responses to peptide 
393-448 and occasionally to peptide 589-644. However, donors from Thailand and Peru had 
much stronger responses to peptide 57-112 (p < 10-6, t-test) (Figure 18C).  These differences may 
reflect variation in the strains endemic in each region. In addition, polymorphism of MHC class 
II alleles, immunoglobulin genes and other modifiers that shape immune responses in each 
population likely play a role in defining the relative immunodominance of antigenic peptides.   
To determine whether the humoral responses that target an immunodominant peptide are 
actually targeting precisely the same epitope, we constructed single-, double-, and triple-alanine 
scanning mutagenesis libraries for 8 commonly recognized peptides. These were introduced into 
the same T7 bacteriophage display vector and subjected to the same immunoprecipitation and 
sequencing protocol using samples from the United States. Mutants that disrupt the epitope 
diminish antibody binding affinity and peptide enrichment. We found that for all 8 peptides 
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tested, there was a single, largely contiguous subsequence in which mutations disrupted binding 
for the majority of samples. As expected, the triple-mutants abolished antibody binding to a 
greater extent, and the enrichment patterns were similar among single-, double- and triple-
mutants of the same peptide (Figure 19 through Figure 26). For 4 of the 8 peptides, a 9 to 15 
amino acid region was critical for antibody recognition in >90% of samples (Figure 19 through 
Figure 22). One other peptide had a region of similar size that was critical in about half of the 
samples (Figure 23). In another peptide, a single region was important for antibody recognition 
in the majority of the samples, but the extents of the critical region varied slightly for different 
samples and occasionally there are donors that recognize a completely separate epitope (Figure 
24). The remaining two peptides contained a single triple mutant that abolished binding in the 
majority of samples, but the critical region also extended further to different extents depending 
on the sample (Figure 25 and Figure 26). Surprisingly, in one of these peptides, in addition to the 
main region surrounding positions 13-14 that is critical for binding, a single G36A mutation 
disrupted binding in almost half of the samples whereas none of the double- or triple-alanine 
mutants that also included the adjacent positions (L35, G37) affected binding (Figure 26). It is 
possible that G36 plays a role in helping the peptide adopt an antigenic conformation and 
multiple-mutants containing the adjacent Leu or Gly residues rescue this ability. We occasionally 
saw other examples of mutations that resulted in patterns of disrupted binding with no simple 
explanation, illustrating the complexity of antibody-antigen interaction. 
The discovery of recurring targeted epitopes led us to ask whether we could apply this 
knowledge to improve the sensitivity of viral detection with VirScan. We hypothesized that 
samples showing a strong response to a recurrently targeted “diagnostic” peptide, which we 
defined as a peptide enriched in at least 30% of known positive samples, are likely to be  
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Figure 19. Recognition of common epitopes within an antigenic peptide from human adenovirus C penton protein 
(L2) across individuals. Each row is a sample. Each column denotes the first mutated position for the (A) single-, 
(B) double-, and (C) triple-alanine mutant peptide starting with the N-terminus on the left. Each double- and triple-
alanine mutant contains two or three adjacent mutations, respectively, extending towards the C-terminus from the 
colored cell. The color intensity of each cell indicates the enrichment of the mutant peptide relative to the wild-type. 
For double-mutants, the last position is blank. The same is true for the last two positions for triple-mutants. Data 
shown are the mean of two replicates. 
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Figure 20. Scanning mutagenesis identification of linear B cell epitopes in an immunogenic peptide from Influenza 
A: hemagglutinin (UniProt ID: H8PET1, positions 1-56). Each row is a sample. Each column denotes the first 
mutated position for (a) single-, (b) double-, and (c) triple-alanine mutant peptides. The color intensity of each cell 
indicates the enrichment of the mutant peptide relative to the wild-type. For double-mutants, the last position is 
blank. The same is true for the last two positions for triple-mutants. Data shown are the mean of two replicates 
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Figure 21. See caption for Figure 20. Respiratory syncytial virus: attachment G glycoprotein (UniProt ID: 
P03276, positions 337-392)  
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Figure 22. See caption for Figure 20. Enterovirus B: genome polyprotein (UniProt ID: Q66474, positions 561-
616). 
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Figure 23. See caption for Figure 20. Enterovirus B: genome polyprotein (UniProt ID: Q6W9F9, positions 1429-
1484). 
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Figure 24. See caption for Figure 20. Rhinovirus A: genome polyprotein (UniProt ID: Q82122, positions 561-616) 
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Figure 25. See caption for Figure 20. Epstein-Barr virus: nuclear antigen 1(UniProt ID: Q1HVF7, positions 393-
448). 
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Figure 26. See caption for Figure 20. Adenovirus C: precapsid vertex protein (UniProt ID: P03279, 
positions 533-585) 
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seropositive even if they do not meet our stringent cutoff requiring at least two non-overlapping 
enriched peptides. We tested how this modified criterion affected our sensitivity and specificity 
in detecting HIV and HCV and found that it reduced the number of false negatives without 
affecting the specificity of the assay (fig. S13). We next turned our attention to respiratory 
syncytial virus (RSV), a virus for which our detected seroprevalence was lower than reported 
epidemiological rates, suggesting imperfect sensitivity of our assay. We tested 60 patient sera for 
antibodies to RSV by ELISA and found 95% were positive, above the reported sensitivity of the 
assay and consistent with near-universal exposure to this pathogen. Applying the modified 
criterion to these samples increased our rate of detection by VirScan from 63% to 97% (Table 4). 
These data suggest that assigning more weight to recurrently targeted epitopes can enhance the 
sensitivity of VirScan and that the performance of the assay can be improved by screening 
known positives for a particular virus. 
 (
Initial  
VirScan algorithm 
RSV ELISA With  
diagnostic peptides 
RSV ELISA 
Positive Negative Positive Negative 
RSV 
VirScan 
Positive 37 1 RSV 
VirScan 
Positive 55 3 
Negative 20 2 Negative 2 0 
Table 4. Modified algorithm applying more weight to diagnostic peptides shows improved detection of antibodies 
against RSV. 60 patient sera were screened for RSV antibodies by ELISA and with VirScan. The concordance of the 
ELISA results with the initial and modified VirScan algorithms is shown in the tables.  
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Discussion(
We have developed VirScan, a technology for identifying viral exposure and B cell 
epitopes across the entire known human virome in a single, multiplex reaction using less than a 
drop of blood. VirScan uses DNA microarray synthesis and bacteriophage display to create a 
uniform, synthetic representation of peptide epitopes comprising the human virome. 
Figure 27. Increased sensitivity after including samples targeting “diagnostic” peptides. For each virus, we 
examined all the samples that enriched multiple peptides that share a single epitope. If this epitope is 
“diagnostic” (i.e., recurrently targeted in at least a threshold fraction of the samples that were originally 
called positive for that virus), we considered the sample to be positive for that virus. The y-axis shows the 
fraction of samples that are considered positive after including these samples. The x-axis represents the 
minimum fraction of the original positive samples that must enrich a peptide for it to be considered 
diagnostic. Using a threshold of 30-70% significantly increases the rate of detecting respiratory syncytial 
virus without significantly increasing the rate of detecting hepatitis C and HIV, which should have low 
seroprevalence in this population (only samples from the United States that were not known HIV or HCV 
positives were included in this analysis). 
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Immunoprecipitation and high-throughput DNA sequencing reveals the peptides recognized by 
antibodies in the sample. VirScan is easily automated in 96-well format to enable high 
throughput sample processing. Barcoding of samples during PCR enables pooled analysis that 
can dramatically reduce the per-sample cost. The VirScan approach has several advantages for 
studying the effect of viruses on the host immune system. By detecting antibody responses, it can 
identify infectious agents that have been cleared after an effective host response. Current 
serological methods of antiviral antibody detection typically employ the selection of a single 
optimized antigen in order to achieve high accuracy. In contrast, VirScan’s unique approach does 
not require such optimization in order to obtain similar performance. VirScan achieves sensitive 
detection by assaying each virus's complete proteome to detect any antibodies directed to 
epitopes that can be captured in a 56-residue fragment and specificity by computationally 
eliminating cross-reactive antibodies. This unbiased approach identifies exposure to less well-
studied viruses for which optimal serological antigens are not known and can be rapidly 
extended to include new viruses as they are discovered (22).  
While sensitive and selective, VirScan also has a few limitations. First, it cannot detect 
epitopes that require post-translational modifications. Secondly, it cannot detect epitopes that 
involve discontinuous sequences on protein fragments greater than 56 residues.  In principle, the 
latter can be overcome by using alternative technologies that allow for the display of full-length 
proteins such as Parallel Analysis of Translated ORFs (PLATO) (85). Third, VirScan is likely to 
be less specific compared with certain nucleic acid tests that discern highly related virus strains. 
However, VirScan demonstrates excellent serological discrimination among similar virus 
species, such as HSV1 and HSV2 and can even distinguish the genotype of HCV 69% of the 
time. We envision VirScan will become an important tool for first-pass unbiased serologic 
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screening applications. Individual viruses or viral proteins uncovered in this way can 
subsequently be analyzed in further detail using more focused assays, as we have demonstrated 
for a panel of immunodominant epitopes. 
We have demonstrated that VirScan is a sensitive and specific assay for detecting 
exposure to viruses across the human virome. Because it can be performed in high-throughput 
and requires minimal sample and cost, VirScan enables rapid and cost-effective screening of 
large numbers of samples to identify population-level differences in virus exposure across the 
human virome. In this work, we analyzed over 106 million antibody-viral peptide interactions in 
a comprehensive study of pan-virus serology in a large, diverse population. In doing so we 
detected 84 different viral species in 2 or more individuals.  This is likely to be an underestimate 
of the history of viral infection as only low levels of circulating antibodies may remain from 
infections that were cleared in the distant past.  In addition, an individual could be infected by 
multiple distinct strains of each viral species. We identified known and novel differences in virus 
exposure between groups differing in age, HIV status, and geographic location across four 
different continents. Our results are largely consistent with previous studies, validating the 
effectiveness of VirScan. For example, cytomegalovirus antibodies were found in significantly 
higher frequencies in Peru, Thailand, and South Africa whereas Kaposi’s sarcoma-associated 
herpesvirus and HSV1 antibodies were detected more frequently in Peru and South Africa, but 
not in Thailand (76, 86–90). We also uncovered previously undocumented serological 
differences, such as an increased rate of antibodies against Adenovirus B and respiratory 
syncytial virus in HIV positive individuals compared to HIV negative individuals. These 
differences may provide insight into how HIV co-infection alters the balance between host 
immunity and resident viruses, as well as help to identify pathogens that may increase 
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susceptibility to HIV and other heterologous infections.  HIV infection may reduce the immune 
system’s ability to control reactivation of normally dormant resident viruses or to prevent 
opportunistic infections from taking hold and triggering a strong adaptive immune response. 
Beyond the epidemiological applications demonstrated here, VirScan could also be applied to 
identify viral exposures that correlate with disease or other phenotypes in virome-wide 
association studies.   
Our results identified a large number of novel B cell epitopes, cumulatively nearly 
doubling the number of all previously identified viral epitopes. We have utilized our data to 
identify globally immunodominant and commonly recognized “public” epitopes. For most 
species of viruses, one or more peptides are individually recognized in over 70% to 95% of 
samples positive for that species (table S3). We identified a set of two peptides that together are 
recognized by >95% of all screened samples and a set of five peptides that together are 
recognized in >99% of screened samples.  
These public epitopes could be used to improve vaccine design by piggybacking on the 
existing antibody response against them. Fusing a public B cell epitope to a protein in a vaccine 
to which we hope to induce an immune response may increase a vaccine’s efficacy among a 
broad population by improving presentation of that protein and aiding affinity maturation. Pre-
existing B cells recognizing the public epitope can act as antigen presenting cells to process and 
present T cell epitopes of the fused vaccine target on MHC class I and II (91). Antibodies 
secreted by these B cells can also participate in immune complexes with the fused vaccine target, 
which are critical for follicular dendritic cells to prime class switching and affinity maturation of 
B cells recognizing other epitopes on the fused antigen (92). Finally, we demonstrated that  
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Species Protein Peptide % 
Rhinovirus B Genome polyprotein 
QTVALTEGLGDELEEVIVEKTKQTVASI 
SSGPKHTQKVPILTANETGATMPVLPSD 95% 
Human herpesvirus 5 Envelope glycoprotein M 
TASGEEVAVLSHHDSLESRRLREEEDDD 
DDEDFEDA 90% 
Enterovirus B Genome polyprotein 
PFIQQEAKLQGEPGKAIESAISRVADTISS 
GPTNSEQVPALTAAETGHTSQVVPGD 86% 
Human respiratory 
syncytial virus 
Attachment 
glycoprotein 
NKPSTKPRPKNPPKKPKDDYHFEVFNFV 
PCSICGNNQLCKSICKTIPSNKPKKKPT 85% 
Human herpesvirus 4 Epstein-Barr nuclear antigen 1 
SPPRRPPPGRRPFFHPVAEADYFEYHQEG 
GPDGEPDMPPGAIEQGPADDPGEGPST 81% 
Human herpesvirus 1 Envelope glycoprotein D RRHTQKAPKRIRLPHIREDDQPSSHQPLFY 80% 
Norwalk virus Genome polyprotein 
LSSMAVTFKRALGGRAKQPPPRETPQRPP 
RPPTPELVKKIPPPPPNGEDELVVSYS 77% 
Human adenovirus C Pre-histone-like nucleoprotein 
MTQGRRGNVYWVRDSVSGLRVPVRTRP 
PRN 74% 
Enterovirus C Genome polyprotein 
QGALTLSLPKQQDSLPDTKASGPAHSKE 
VPALTAVETGATNPLAPSDTVQTRHVVQ 73% 
Human herpesvirus 3 Envelope glycoprotein C 
PDPAVAPTSAASRKPDPAVAPTSAASRK 
PDPAVAPTSAATRKPDPAVAPTSAASRK 72% 
Human 
immunodeficiency 
virus 1 
Envelope 
glycoprotein gp160 
ERYLKDQQLLGIWGCSGKLICTTAVPWNA 
SWSNKSLEQIWNNMTWMEWDREINNYT 60% 
Table 5. Certain peptides are commonly targeted by the antibody response. We determined the peptide from each 
species of virus that was most frequently targeted in donors that were exposed to that virus. In each row, the 
frequency is the percentage of samples positive for the species of virus that had antibodies targeting the peptide 
sequence shown. The parent protein of the peptide is also listed.  
applying more weight to these public epitopes increases the sensitivity of VirScan without 
significantly affecting specificity, suggesting that this limited subset of peptides can serve as the 
basis for the next generation of our assay or for other novel diagnostics.   
We also found that the precise epitopes recognized by the B cell response are highly 
similar among individuals across many viral proteins. One possible model for this striking 
similarity is that these regions possess properties favorable for antigenicity, such as accessibility. 
Another model is that the same or highly similar B cell receptor sequences that recognize these 
epitopes are commonly generated. Identical T cell receptor sequences (“public” clonotypes) have 
been found in multiple individuals and are thought to be the result of biases during the 
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recombination process that favor certain amino acid sequences (93). V(D)J recombination of the 
immunoglobulin heavy and light chain loci is also heavily biased (94). Highly similar or even 
identical complementarity determining region 3 (CDR3) sequences have been observed in 
dengue virus specific antibodies from different individuals (95). It is possible that, rather than 
being an exception for dengue specific antibodies, this represents a general phenomenon: 
inherent biases in V(D)J recombination generate the same or similar antibodies in multiple 
individuals that recognize highly similar epitopes. Slight differences in the antibody CDR3 
sequence may subtly alter antibody-antigen interaction, leading to the slight variations observed 
in the extent of critical epitope regions. Sequencing of antigen specific antibody genes will be 
required to investigate these possibilities. The same principle may also apply to T cell epitopes 
and their cognate TCRs. 
In conclusion, VirScan is a new method that enables human virome-wide exploration - at 
the epitope level - of immune responses in large numbers of individuals. We have demonstrated 
its effectiveness for determining viral exposure and characterizing viral B cell epitopes in high 
throughput and at high resolution. Our preliminary studies have revealed intriguing general 
properties of the human immune system, both at the individual and population scale. VirScan 
will be an important tool in uncovering the effect of host-virome interactions on human health 
and disease and could easily be expanded to include other human pathogens such as bacteria, 
fungi and protozoa. 
Supplementary(Discussion(
Estimating(VirScan’s(specificity(
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Although we detected antibody responses to rare and highly virulent viruses such as 
Marburg and bat lyssavirus, they were found in less than 1% of the population (Table 3), 
indicating that specificity is over 99% for these viruses, which is similar to the results in Table 2. 
Because we screened hundreds of sera for recognition of 206 virus species each, we performed 
the equivalent of approximately 100,000 individual tests, and eliminating such false positives 
altogether would require specificity of approximately 99.999% for each virus. Even with 99% 
specificity, a test will have 1% false positives, or approximately three per virus species for the 
303 samples in population analyzed in Table 3. 
 In addition, 92 species of virus out of 206 were not detected in any samples from this 
population. Another 45 were detected in 3 or fewer samples. Assuming these are all false 
positives, which errs on the side of overestimating false positives, this analysis suggests that the 
specificity is 99.9%.  While this is an imperfect estimate because we do not know how many of 
the detected positives are actually false positives, it gives an approximate estimate that argues the 
specificity is very high. No assay is perfect, and even highly optimized ELISAs for single viruses 
have some level of false positive, but our results give us a great deal of confidence in VirScan’s 
specificity. 
Differentially(weighting(recurrent(peptides(increases(sensitivity(
After discovering that certain epitopes are recurrently targeted, we examined whether we 
could apply this knowledge to improve the sensitivity of viral detection with VirScan. Recurrent 
epitopes make up a very small portion of a virus’s proteome. On average, less than 1% of a given 
virus’s proteome is targeted in more than 30% of samples positive for that virus. We 
hypothesized that samples showing a strong response to these recurrently targeted “diagnostic” 
peptides, which we defined as a peptide enriched in at least 30% of positive samples, are likely 
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to be seropositive even if they do not meet our stringent cutoff requiring at least two non-
overlapping enriched peptides. Thus, we introduced a modified criterion for calling a sample 
positive for a given virus that only requires one unique enriched peptide from the virus as long as 
the peptide is diagnostic (i.e., enriched in at least 30% of the samples that were originally called 
positive for that virus) and at least one other peptide that shares at least 7aa sequence homology 
was also enriched. The requirement for enrichment of two or more related peptides guards 
against potentially spurious technical enrichments.   
We tested how this modified criterion affected our sensitivity and specificity in the 
known HCV positive and negative samples. In this set of samples, we had two false negatives, 
which had 11 and 14 enriched peptides, respectively, that were highly homologous and thus 
filtered down to one unique epitope. In both samples, this epitope corresponded to the N-
terminus of the genome polyprotein, which is targeted in over 70% of the HCV positive samples. 
Thus, the modified criterion increases sensitivity for HCV to 100%. This modified criterion does 
not lead to increased false positives among known HCV negative samples nor does it 
significantly increase the rate of detecting HCV positive samples among the rest of the US 
samples (Figure 27). 
We then tested how this modified criterion works on the known HIV positive and 
negative samples. Of the four false negative samples, one had enriched six related peptides 
targeted in 70-90% of the HIV positive samples and would be considered positive using the 
modified criterion. This relaxed criterion does not lead to increased false positives among known 
HIV negative samples nor does it increase the rate of detecting HIV positive samples among the 
rest of the US samples (Figure 27). The remaining three false negative samples did not 
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significantly enrich a recurrently targeted peptide. However, upon further examination, we found 
that in two of the samples, although no single recurrent peptide was enriched, the set of 
recurrently targeted peptides were, as a group, enriched relative to other HIV peptides using a 
modified Gene Set Enrichment Analysis approach (Figure 28). These results suggest that these 
false negatives are due to low titers of anti-HIV antibodies that do not pass our stringent 
threshold for significance for any one peptide, but are significant when the set of homologous 
peptides are considered together. Once recurring peptides are identified for a given virus, this 
methodology could be used to develop a secondary analysis criterion for suspected false 
negatives, especially those that present with some but too few scoring peptides to meet the 
threshold for consideration as a positive.  
We next turned our attention to respiratory syncytial virus (RSV), a virus for which our 
detected seroprevalence was lower than reported epidemiological rates, suggesting imperfect 
sensitivity of our assay. We tested 60 patient sera for antibodies to RSV by ELISA and found 
95% were positive, above the reported sensitivity of the assay and consistent with near-universal 
exposure to this pathogen. Applying the modified criterion to these samples increased our rate of 
detection by VirScan from 63% to 97% (Table 4). These data suggest that assigning more weight 
to recurrently targeted epitopes can enhance the sensitivity of VirScan and that the performance 
of the assay can be improved by screening known positives for a particular virus to discover 
these recurrently targeted epitopes. 
 
 (
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Methods(
Design(and(cloning(of(viral(peptide(and(scanning(mutagenesis(library(sequences(
Figure 28. Peptide set enrichment analysis for peptides containing recurrent epitopes in HIV samples. The 
analysis and graph are similar to the enrichment score calculation for the Gene Set Enrichment Analysis method. 
For each sample, the HIV peptides that did not pass our threshold for significantly enriched were ranked in 
descending order of -log10(p-value). A running sum was calculated by going down the list and, if the peptide was 
recurrently targeted in HIV (enriched in the majority of the HIV positive samples), the running sum was 
incremented by a value weighted by the -log10(p-value) of the peptide and normalized to 1 for all recurrent 
peptides. Otherwise, the running sum was decrement by a fixed value that was normalized to 1 for all non-
recurrent peptides. The running sum is plotted for the 31 HIV negative samples (black lines) and for the HIV false 
negative samples (blue, green, and red lines). The maximum positive displacement of the running sum (enrichment 
score) is a measure of how significantly the set of peptides is enriched relative to the other HIV peptides. 
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For the virome peptide library, we first downloaded all protein sequences in the UniProt 
database from viruses with human host and collapsed on 90% sequence identity 
(http://www.uniprot.org/uniref/?query=uniprot:(host: "Human+[9606]")+identity:0.9). The 
clustering algorithm UniProt represents each group of protein sequences sharing at least 90% 
sequence similarity with a single representative sequence. Then, we created 56 aa peptide 
sequences tiling through all the proteins with 28 aa overlap. We reverse translated these peptide 
sequences into DNA codons optimized for expression in E. coli, making synonymous mutations 
when necessary to avoid restriction sites used in subsequent cloning steps (EcoRI and XhoI). 
Finally, we added the adapter sequence “aGGAATTCCGCTGCGT” to the 5’ end and 
“CAGGgaagagctcgaa” to the 3’ end to form the 200 nt oligonucleotide sequences.  
For the scanning mutagenesis library, we first took the sequences of the peptides to be 
mutagenized. For each peptide, we made all single-mutants, and consecutive double- and triple-
mutants sequences scanning through the whole peptide. Non-alanine amino acids were mutated 
to alanine and alanines were mutated to glycine. We reverse translated these peptide sequences 
into DNA codons, making synonymous mutations when necessary to avoid restriction sites used 
in subsequent cloning steps (EcoRI and XhoI). We also made synonymous mutations to ensure 
that the 50 nt at the 5’ end of peptide sequence is unique to allow unambiguous mapping of the 
sequencing results. Finally, we added the adapter sequence “aGGAATTCCGCTGCGT” to the 5’ 
end and “CAGGgaagagctcgaa” to the 3’ end to form the 200 nt oligonucleotide sequences. 
The 200 nt oligonucleotide sequences were synthesized on a releasable DNA microarray.  
We PCR amplified the DNA using the primers T7-PFA (aatgatacggcggGAATTCCGCTGCGT) 
and T7-PRA (caagcagaagACTCGAGCTCTTCCCTG), digested the product with EcoRI and 
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XhoI, and cloned the fragment into the EcoRI/SalI site of the T7FNS2 vector (19). The resulting 
library was packaged into T7 bacteriophage using the T7 Select Packaging Kit (EMD Millipore) 
and amplified using the manufacturer suggested protocol. 
Phage(immunoprecipitation(and(sequencing(
We performed phage immunoprecipitation and sequencing using a slightly modified 
version of previously published PhIP-Seq protocols (19, 70). First, we blocked each well of a 96 
deep-well plate with 1 mL of 3% BSA in TBST overnight on a rotator at 4ºC. To each pre-
blocked well, we added sera or plasma containing approximately 2 µg of IgG (quantified using a 
Human IgG ELISA Quantitation Set (Bethyl Laboratories)) and 1 mL of the bacteriophage 
library diluted to approximately 2×105 fold representation (2×1010 pfu for a library of 105 clones) 
in phage extraction buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 6 mM MgSO4). We 
performed two technical replicates for each sample. We allowed the antibodies to bind the phage 
overnight on a rotator at 4ºC. The next day, we added 20 µL each of magnetic Protein A and 
Protein G Dynabeads (Invitrogen) to each well and allowed immunoprecipitation to occur for 4 h 
on a rotator at 4ºC. Using a 96-well magnetic stand, we then washed the beads three times with 
400 µL of PhIP-Seq wash buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% NP-40). After 
the final wash, we resuspended the beads in 40 µL of water and lysed the phage at 95 ºC for 10 
m. We also lysed phage from the library before immunoprecipitation (“input”) and after 
immunoprecipitation with beads alone. 
We prepared the DNA for multiplexed Illumina sequencing using a slightly modified 
version of a previously published protocol (96). We performed two rounds of PCR amplification 
on the lysed phage material using hot start Q5 polymerase according to the manufacturer 
suggested protocol (NEB). The first round of PCR used the primers IS7_HsORF5_2 
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(ACACTCTTTCCCTACACGACTCCAGTCAGGTGTGATGCTC) and IS8_HsORF3_2 
(GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCCGAGCTTATCGTCGTCATCC). The 
second round of PCR used 1 µL of the first round product and the primers IS4_HsORF5_2 
(AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACTCCAGT) and a 
different unique indexing primer for each sample to be multiplexed for sequencing 
(CAAGCAGAAGACGGCATACGAGATxxxxxxxGTGACTGGAGTTCAGACGTGT, where 
“xxxxxxx” denotes a unique 7 nt indexing sequence). After the second round of PCR, we 
determined the DNA concentration of each sample by qPCR and pooled equimolar amounts of 
all samples for gel extraction. Following gel extraction, the pooled DNA was sequenced by the 
Harvard Medical School Biopolymers Facility using a 50 bp read cycle on an Illumina HiSeq 
2000 or 2500. We pooled up to 192 samples for sequencing on each lane and generally obtained 
approximately 100 - 200 million reads per lane (500,000 to 1,000,000 reads per sample).  
Informatics(and(statistical(analysis(
We performed the initial informatics and statistical analysis using a slightly modified 
version of the previously published technique (19, 70). We first mapped the sequencing reads to 
the original library sequences using Bowtie and counted the frequency of each clone in the 
“input” and each sample “output” (62). Since the majority of clones are not enriched we use the 
observed distribution of output counts as a null distribution. We found that a zero-inflated 
generalized poisson distribution fits our output counts well. We use this null distribution to 
calculate a p-value for the likelihood of enrichment for each clone. The probability mass function 
for the zero-inflated generalized poisson distribution is 
푃 푌 = 푦 = 휋+ (1 − 휋)(휃 휃+ 휆 푥'(푒'휃'푥휆), 푦 = 0(1 − 휋)(휃 휃+ 휆 푥'(푒'휃'푥휆), 푦 > 0 
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We used maximum likelihood estimation to regress the parameters , , and  to fit 
the distribution of counts after immunoprecipitation for all clones present at a particular 
frequency count in the input. We repeated this procedure for all of the observed input counts and 
found that  and  are well fit by linear regression and  by an exponential regression as a 
function of input count (Figure 9). Finally, for each clone we used its input count and the 
regression results to determine the null distribution based on the zero-inflated generalized 
poisson model, which we used to calculate the -log10(p-value) of obtaining the observed count. 
To call hits, we determined the threshold for reproducibility between technical replicates 
based on a previously published method (70). Briefly, we made scatter plots of the log10 of the -
log10 (p-values) and used a sliding window of width 0.005 from 0 to 2 across the axis of one 
replicate. For all the clones that fell within each window, we calculated the median and median 
absolute deviation of the log10 of the –log10 (p-values) in the other replicate and plotted it 
against the window location (Figure 10). We called the threshold for reproducibility the first 
window in which the median was greater than the median absolute deviation. We found that the 
distribution of the threshold –log10 (p-value) was centered around a mean of approximately 2.3 
(Figure 14). So we called a peptide a hit if the –log10 (p-value) was at least 2.3 in both 
replicates. We eliminated the 593 hits that came up in at least three of the twenty-two 
immunoprecipitations with beads alone (negative control for non-specific binding). We also 
filtered out any peptides that were not enriched in at least two of the samples.  
To call virus exposures, we grouped peptides according to the virus the peptide is derived 
from. We grouped all peptides from individual viral strains for which we had complete 
proteomes. The sample was counted as positive for a species if it was positive for any strain from 
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that species. For viral strains that had partial proteomes, we grouped them with other strains from 
the same species to form a complete set and bioinformatically eliminated homologous peptides 
(see next paragraph). We set a threshold number of hits per virus based on the size of the virus. 
We found that there is approximately a power-law relationship between size of the virus and the 
average number of hits per sample (Figure 12). In comparing results from VirScan to samples 
with known infection, we empirically determined that a threshold of 3 hits for herpes simplex 
virus 1 worked the best. We used this value and the slope of the best fit line to scale the threshold 
for other viruses. We also set a minimum threshold of at least 2 hits in order to avoid false 
positives from single spurious hits. 
To bioinformatically remove cross-reactive antibodies, we first sorted the viruses by total 
number of hits in descending order. We then iterated through each virus in this order. For each 
Figure 29. Distribution of reproducibility threshold -log10(p-values). Histogram of the frequency of the 
reproducibility threshold -log10(p-values). The mean and median of the distribution are both approximately 2.3. 
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virus, we iterated through each peptide hit. If the hit shared a subsequence of at least 7 aa with 
any hit previously observed in any of the viruses from that sample, that hit was considered to be 
from a cross-reactive antibody and would be ignored for that virus. Otherwise, the hit is 
considered to be specific and the score for that virus is incremented by one. In this way, we 
summed only the peptide hits that do not share any linear epitopes. We compared the final score 
for each virus to the threshold for that virus to determine whether the sample is positive for 
exposure to that virus. 
To identify differences between populations, we first used Fisher’s exact test to calculate 
a p-value for the significance of association of virus exposure with one population versus 
another. Then, we constructed a null-distribution of Fisher’s exact p-values by randomly 
permuting the sample labels 1000 times and re-calculating the Fisher’s exact p-value for each 
virus. Using this null-distribution, we calculated the false discovery rate by dividing the number 
of permutation p-values more extreme than the one observed by the total number of 
permutations. 
IEDB(epitope(overlap(analysis(
We downloaded data for all continuous human B cell epitopes from IEDB and filtered 
out all non-viral epitopes (83). To avoid redundancy in these 4,549 viral epitopes, we grouped 
together epitopes that are 100% identical or share a 7 aa subsequence, giving us 1,559 non-
redundant epitope groups. Of these groups, 1,392 contain a member epitope that is also a 
subsequence of a peptide in the VirScan library. This represents the total number of epitopes we 
could detect by VirScan. To determine the number of epitopes we detected, we tallied the 
number of epitope groups with at least one member that is contained in a peptide that was 
enriched in one or two samples. Finally, to determine the number of non-redundant new epitopes 
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we detected, we grouped non-IEDB epitopes containing peptides that share a 7 residues 
subsequence and counted the number of these non-redundant peptide groups. 
Scanning(mutagenesis(data(analysis(
First, we estimated the fractional abundance of each peptide by dividing the number of 
reads for that peptide by the total number of reads for the sample. Then, we divided the fractional 
abundance of each peptide after immunoprecipitation by the fractional abundance before 
immunoprecipitation to get the enrichment. To calculate relative enrichment, we divided 
enrichment of the mutated peptide by enrichment of the wild-type peptide. Since most of the 
single-mutant peptides had wild-type levels of enrichment, we averaged enrichment of the wild-
type peptide enrichment with the middle two quartiles of enrichment of single-mutant peptides to 
get a better estimate of the wild-type peptide enrichment. 
Respiratory(syncytial(virus(and(Herpesvirus(1(and(2(serology(
Serum from 44 donors was tested for Herpesvirus 1 and Herpesvirus 2 antibodies using 
the HerpeSelect® 1 and 2 Immunoblot IgG kit (Focus Diagnostics) according to manufacturer’s 
protocol. Serum from 60 donors was tested for Respiratory syncytial virus antibodies using Anti-
Respiratory syncytial virus (RSV) IgG Human ELISA Kit (ab108765) according to 
manufacturer’s protocol.  
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Introduction(
Scleroderma, also known as systemic sclerosis (SSc), is a chronic autoimmune rheumatic 
disease with a prevalence of 50 to 300 cases per 1 million persons and an incidence of 2.3 to 22.8 
cases per 1 million persons per year (97). Patients with SSc develop a complex mixture of 
pathologies including vasculopathy and fibrosis of the skin and internal organs which can lead to 
death, most commonly by involvement of the heart and lungs leading to pulmonary fibrosis and 
pulmonary arterial hypertension (PAH) (98). The exact cause of SSc is still unknown, but the 
early stages of disease are believed to be triggered by endothelial cell injury and apoptosis (24). 
SSc has been classified as an autoimmune disease because autoantibodies are frequently 
found in patients. In fact, approximately 90% of patients with SSc have antinuclear antibodies 
(24). Researchers have discovered that up to 50% of patients with SSc fall into one of three 
generally mutually exclusive subclasses which have autoantibodies targeting either the 
centromere, topoisomerase 1, or RNA polymerase III (Pol III) (25). Several reports have 
demonstrated different prognoses associated with these three subclasses (97, 99–101), but the 
origin of the autoantibodies and their role, if any, in the initiation and progression of disease is 
still largely unknown.  
The results of a recent study suggested that anti-Pol III autoantibodies may arise from a 
specific T cell response against a tumor mutation-associated neoantigen which primes cross-
reactive antibody response against the wild-type version of Pol III (26). The study was motivated 
by a previous observation that patients with SSc and anti-Pol III autoantibodies tend to have 
coincident onset of SSc and cancer (27). The same was not true for patients with autoantibodies 
against either the centromere or topoisomerase1, but many patients with autoantibodies that did 
not fall into any of the three subclasses did have coincident cancer. We decided to study sera 
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from these patients to look for novel autoantibody specificities that may be associated with 
coincident cancer using the Phage-Immunoprecipiation Sequencing (PhIP-Seq) and Parallel 
Analysis of Translated Open Reading Frames (PLATO) techniques previously developed by our 
laboratory. 
Both techniques can identify the antigen targets of antibodies in serum by 
immunoprecipitation in the presence of a mixture of potential protein antigens, each of which is 
associated with the DNA that encodes it. High-throughput sequencing of the mixture of DNA 
molecules before and immunoprecipitation reveals which protein antigens were enriched due to 
binding by antibodies in the sample. PhIP-Seq and PLATO differ in the method of protein 
display and the type of DNA encoding the displayed protein.  In PhIP-Seq, the DNA are 
oligonucleotides originally synthesized on programmable microarrays that are displayed on the 
surface of bacteriophage as fusions to its coat protein (19). In PLATO, the DNA are a collection 
of full-length open reading frames that are expressed using ribosome display (85). 
For PhIP-Seq, our laboratory has a collection of oligonucleotides encoding 90 amino acid 
protein fragments tiling through the entire human proteome with 45 amino acid overlap cloned 
into a T7 bacteriophage display vector. This reagent offers a complete and much more uniform 
representation of the human proteome compared to traditional cDNA expression libraries 
previously used to identify unknown autoantibody targets. However, because high-yield 
synthesis of longer DNA sequences at scale is not yet possible, PhIP-Seq is limited to display of 
protein fragments. Many antibodies recognize discontinuous epitopes that may not be captured in 
a 90 amino acid protein fragment. The PLATO technique, which displays full-length proteins, 
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overcomes this limitation. However, none of the human open reading frame collections contain 
the complete proteome, so there is gaps in PLATO’s coverage. 
We used these two complementary techniques to screen serum samples from patients 
with SSc and several others, including healthy donors and patients with other autoimmune 
diseases. We looked for novel autoantibody specificities in the patients with SSc who did not 
belong to any of the three known subclasses and determined if any newly identified subclasses 
were associated with coincident cancer. 
Results(
Confirmation(of(anti;Pol(III(autoantibody(status(
In our collaboration with Antony Rosen and Livia Casciola-Rosen at the Johns Hopkins 
School of Medicine, we obtained 48 serum samples from patients with SSc. Of these patients, 32 
had autoantibodies against Pol III, as detected by prior serum ELISA or immunoprecipitation-
Western blot (IP-WB) analysis. The remaining 16 did not have detectable autoantibodies against 
Pol III, topoisomerase 1, or centromeres but did have coincident cancer onset. We first assayed 
all of these samples using PhIP-Seq to identify their autoantibody specificities. 
To assess PhIP-Seq’s performance on these samples, we analyzed our ability to detect the 
known autoantibodies against Pol III. We detected autoantibodies against at least one subunit of 
Pol III in 27 of the 32 samples that had known anti-Pol III autoantibodies and 0 of the 16 
samples that did not (Figure 30). These 32 samples were originally identified as positive for anti-
Pol III autoantibodies using serum ELISA or IP-WB with the polymerase (RNA) III (DNA 
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directed) polypeptide A (POLR3A) subunit of the Pol III complex.  PhIP-Seq’s performance on 
the POLR3A subunit alone was actually relatively poor. We detected autoantibodies against 
POLR3A in only 3 of the 32 samples. As briefly mentioned in this chapter’s introduction, the 
discrepancy between the results of PhIP-Seq versus ELISA or IP-WB is likely because the 
bacterially expressed 90 amino acid protein fragments used in PhIP-Seq will not capture 
antibodies that recognize discontinuous epitopes or post-translationally modified epitopes. In 
contrast, ELISA and IP-WB assays using the full-length protein expressed in eukaryotic cells 
will be more sensitive for detecting these antibodies. We wanted to see if PLATO would be more 
sensitive than PhIP-Seq because it uses full-length proteins, but unfortunately POLR3A is not in 
our collection of human ORFs. 
However, our overall performance for detecting anti-Pol III autoantibodies using PhIP-
Seq was still high because we frequently detected autoantibodies to other Pol III subunits, 
Figure 30. Detection of autoantibodies to Pol III subunits in sera from patients with SSc. Each column represents 
a patient with SSc that was screened using the PhIP-Seq assay. The labeled bars below the chart indicate whether 
or not the patient has detectable autoantibodies to Pol III. Each row is a gene that encodes a subunit of the Pol III 
complex. Each cell is colored black if serum from that column’s patient contains autoantibodies to any protein 
fragment of that row’s gene as detected by PhIP-Seq. 
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specifically POLR3F and POLR3H (Figure 30). Subsequent ELISA and IP-WB experiments 
with POLR3F and POLR3H confirmed the prevalence of autoantibodies against these antigens. 
These results are likely evidence of epitope spreading of the autoantibody response within the 
Pol III complex (102). This signature gives greater confidence that the observed autoantibodies 
are part of a true autoimmune response rather than a spurious result due to cross-reactive 
antibody binding or multiple hypothesis testing. 
Identification(of(novel(subclass(with(autoantibodies(against(the(minor(
spliceosome(complex(
Satisfied that the PhIP-Seq assay has high performance on the samples, we next sought to 
identify novel autoantibody specificities in the set of samples from patients without 
autoantibodies against Pol III, topoisomerase 1, or centromeres. To accomplish this, we ranked 
all of the human proteins based on how frequently autoantibodies against them were observed in 
the 16 serum samples without known autoantibody specificities compared to the 32 samples with 
known autoantibody specificities. There were many candidate autoantigens that appeared to be 
more frequent in the set of 16 samples with unknown autoantigens (Figure 31). 
In order to prioritize the candidates for follow-up analysis, we looked for evidence of 
intramolecular epitope spreading. Because PhIP-Seq is performed using protein fragments rather 
than full-length proteins, we are able to discern the presence of multiple antibodies that 
recognize distinct epitopes on the same protein. The candidate autoantigens in which we detect 
intramolecular epitope spreading are more likely to be the result of a true autoimmune response 
and thus should be prioritized for follow-up. 
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In performing the described analyses, we found that the strongest candidate autoantigen 
on our list was RNPC3. We detected auto-antibodies against RNPC3 in 4 of the 16 samples  
without known autoantibody specificities and none of the 32 samples with known specificities. 
Including our results from other screens using PhIP-Seq, we found that autoantibodies against 
RNPC3 were not present in any of 123 serum samples, including ones from healthy donors and 
patients with the autoimmune diseases IgG4-related disease and dermatomyositis. So 
autoantibodies against RNPC3 appear to be a specific marker of SSc. In addition, we saw 
evidence of epitope spreading within RNPC3 in all four of the samples with autoantibodies 
against RNPC3 (Error! Reference source not found.). We observed autoantibodies against the 
same four consecutive protein fragments. This region is not repetitive; the four fragments do not 
have any stretch of four or more amino acids in common. Because the tiling protein fragments 
are 90 amino acids long, with 45 amino acid overlap, detection of autoantibodies against four 
consecutive fragments indicates there are at least two distinct antibodies recognizing separate 
epitopes. Thus, the observed pattern of autoantibodies against RNPC3 is likely the result of 
Figure 31. Ranked list of the top candidate novel autoantigens in SSc. Each column of the chart represents a patient 
with SSc that was screened using the PhIP-Seq assay. The labeled bars above the chart indicate whether or not the 
patient has detectable autoantibodies to Pol III. Each row of both the chart and the adjacent table represents a patient 
serum sample. Each cell is colored black if serum from that column’s patient contains autoantibodies to any protein 
fragment of that row’s gene as detected by PhIP-Seq. The column “Ab-” in the table lists the percentage of samples 
without known autoantibody specificities that have autoantibodies against that row’s gene product. The column 
“Ab+” in the table lists the same except for the samples with known autoantibody specificities. Finally, the column 
“p” in the table lists the p-value of a Fisher’s exact test for whether the autoantibodies against row’s gene product is 
more frequent in the samples without known autoantibody specificities. 
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intramolecular epitope spreading, suggesting there is a true autoimmune response against 
RNPC3. 
RNPC3 encodes RNA-binding protein 40, a member of the minor spliceosome complex which 
participates in removal of U12-type introns from pre-mRNA (103, 104). In three of the four 
samples with autoantibodies against RNPC3, we also detected autoantibodies against PDCD7, 
another member of the minor spliceosome complex (Figure 31). This data suggests that in 
addition to intramolecular epitope spreading within RNPC3, we detected intermolecular epitope 
spreading within the minor spliceosome complex, providing further evidence that we observed a 
true autoimmune response. 
Has$AutoAb to$Pol$IIINo$AutoAb to$Pol$III,topo$I,$or$centromere
Figure 32. Evidence for intramolecular epitope spreading in RNPC3. Each column of the chart represents a patient 
with SSc that was screened using the PhIP-Seq assay. The labeled bars before the chart indicate whether or not the 
patient has detectable autoantibodies to Pol III. Each row of the chart represents one of the 90 amino acid protein 
fragments tiled through the entire RNPC3 gene (1 is the N-terminal fragment). The color of each cell represents 
the -log10(p-value) for enrichment of that row’s protein fragment in that column’s sample. Greater confidence in 
the detection of an autoantibody is indicated by a darker color (larger -log10(p-value)), as labeled on the scale in 
the colorbar to the right of the chart.  
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Confident that we were observing a true autoantibody response against RNPC3 that was 
specific to patients with SSc, we asked our collaborators, Antony Rosen and Livia Casciola-
Rosen, to perform IP-WBs using RNPC3 with these and other samples from patients with SSc.  
 Coincident Cancer No coincident cancer Totals 
Has autoantibodies to 
Pol III, topo 1, or 
centromere 
0/25 0/42 0/67 
No autoantibodies to 
Pol III, topo 1, or 
centromere 
10/69 8/61 18/130 
Totals 10/94 8/103 18/197 
Table 6. Patients with autoantibodies against RNPC3 are a novel subclass of SSc. The numbers in the table 
represent the fraction of samples with autoantibodies to RNPC3, with the denominator representing the total number 
of samples that fit the criteria specified in the row and column labels. The main rows split the samples into ones that 
have known autoantibody specificities and ones that do not. The main columns split the samples into ones that have 
coincident cancer and ones that do not. The marginal rows and columns are totals summed across the rows or 
columns, respectively. 
Their results confirmed our findings in this set of 48 samples and also found 14 
additional cases of patients with SSc with autoantibodies against RNPC3 among other samples in 
their repository. In total, 18 of 197 patients with SSc that were tested by IP-WB had 
autoantibodies against RNPC3 (Error! Reference source not found.). Similar to what has been 
observed with the three known subclasses, this novel subclass was mutually exclusive with all of 
the other subclasses. None of the 18 had autoantibodies against Pol III, topoisomerase 1, or 
centromeres. We also looked to see if autoantibodies against RNPC3 were associated with 
coincident cancer, as had previously been observed for patients with autoantibodies against 
POLR3A (27). There was a very slightly higher frequency of coincident cancer in patients with 
autoantibodies against (10 with coincident cancer versus 8 without coincident cancer), but the 
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difference was not statistically significant (Error! Reference source not found.). However, 
these data do not preclude the possibility that the 8 patients did indeed have coincident 
malignancies, but that the nascent tumors were controlled by the immune system before they 
progressed enough to be diagnosed.  
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Table 7. Top candidate autoantigens associated with the subclass of patients with SSc who have autoantibodies 
against RNPC3 detected by PhIP-Seq. The first two columns indicate the gene and position of the protein fragment 
each row refers to. The first position is the N-terminal 90 amino acid fragment and each consecutive position is the 
next 90 amino acid fragment with 45 amino acid overlap. The “+” and “-” columns under the “RNPC3+” heading 
indicate the number of samples with autoantibodies against RNPC3 that did or did not have detectable 
autoantibodies against that row’s protein fragment, respectively. The “+” and “-” columns under the “not 
RNPC3+” heading represent the same except for the 123 control samples. The final column is the p-value for a 
Fisher’s exact test for whether autoantibodies against that row’s protein fragment is more frequent in the 
“RNPC3+” group compared to the “not RNPC3+” group. 
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We performed two more screens to determine if there are any more autoantibody 
specificities associated with this novel RNPC3 subclass. For the first screen, we used PhIP-Seq 
and looked for autoantibody specificities that were more frequent in the 18 samples with 
autoantibodies against RNPC3, as identified by IP-WB analysis using recombinant RNPC3 
Table 8. Top candidate autoantigens detected by PLATO in the four patients with SSc who have autoantibodies 
against RNPC3. Each row shows data corresponding to the candidate autoantigen gene listed in the first 
column. The remaining four columns show the fold-change in relative abundance for each gene after 
immunoprecipitation with patient serum compared to beads alone (see Methods). The data in each of the 
columns were obtained from the sample identified in the column label. The data are sorted in descending order 
based on fold-change in sample “FW-1089”, but RNPC3, SNRNP25, and SNRNP35 are in the top 5 greatest 
fold-change in “FW-0446” and “FW-1782”. 
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antigen, than in 123 control samples, including samples from health donors and patients with 
other autoimmune diseases such as IgG4-related disease and dermatomyositis. These 18 samples 
included the four in which PhIP-Seq had previously detected autoantibodies against three to four 
peptides each, at least two of which were non-overlapping (Figure 32). As expected, three of the 
top five candidates were peptides derived from RNPC3 (Error! Reference source not found.). 
These autoantigenic peptides were the same ones detected in the original four samples, and 
several of the samples had autoantibodies against multiple of these peptides. The top non-
RNPC3 candidate was a peptide from SNRNP48, which, like RNPC3 and PDCD7 previously, is 
a component of the minor spliceosome complex. 
For the second screen, we used PLATO on the four samples we had originally identified 
with autoantibodies against RNPC3. In three of the four samples, RNPC3 was the most or 
second most strongly enriched ORF, further confirming our PhIP-Seq results (Error! Reference 
source not found.). The remaining sample had poor enrichment across all of the ORFs, perhaps 
because there was an issue with RNA degradation in that reaction. In addition to RNPC3, we 
found that SNRNP25 and SNRNP35, both components of the minor spliceosome complex, were 
also significantly enriched in the same three samples. Our PhIP-Seq screens did not detect 
significant enrichment of protein fragments derived from these two proteins in these three 
samples, perhaps because of PLATO is more sensitive for detecting antibodies against 
discontinuous epitopes, as discussed in this chapter’s introduction. 
Combining the results of all our screens, we discovered that patients in this novel 
subclass of SSc have autoantibodies against many components of the minor spliceosome 
complex (Table 9). These results provide strong evidence that this novel subclass of patients with 
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SSc share the distinct pathological feature of an autoimmune humoral response against the minor 
spliceosome complex. 
Protein (Gene) 
Autoantibodies 
detected 
by PhIP-Seq 
Autoantibodies 
detected 
by PLATO 
Sm proteins1   
SF3b complex2   
20K (ZMAT5)   
25K (SNRNP25)  ✓ 
31K (ZCRB1)   
35K (SNRNP35)  ✓ 
48K (SNRNP48) ✓  
59K (PDCD7) ✓  
65K (RNPC3) ✓ ✓ 
Urp (ZRSR2)   
hPrp43 (DHX15)   
Y Box-1 (YBX1)   
Table 9. Discovery of autoantibodies against multiple components of the minor spliceosome complex. Each row 
represents one of the protein components of the minor spliceosome complex (105) as indicated by the label in the 
first column (gene names in parentheses). Checkmarks in next two columns indicate whether autoantibodies to that 
protein were identified by PhIP-Seq, PLATO, or both. 
1 Sm proteins B/B’, D1, D2, D3, E, F, and G 
2 multi-subunit complex 
Discussion(
In this study, we have demonstrated the power of combining the two complementary 
approaches developed in our laboratory, PhIP-Seq and PLATO, for identifying autoantibody 
specificities in large, heterogeneous populations. Although PhIP-Seq has the advantages of being 
high throughput and a complete synthetic representation of the human proteome at the protein 
fragment level, it can miss antibodies that recognize discontinuous epitopes. In contrast, PLATO 
is lower throughput and does not provide complete coverage of the human proteome in its 
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current form, but will detect antibodies against discontinuous epitopes. Thus, although both 
techniques could detect autoantibodies against RNPC3, other autoantibody specificities were 
only detectable by either only PhIP-Seq or only PLATO. 
Combining the results from the PhIP-Seq and PLATO screens revealed a novel subclass 
of patients with SSc with autoantibodies against the minor spliceosome complex. Our results 
indicate significant intramolecular epitope spreading within RNPC3 and intermolecular epitope 
spreading within the entire complex. This immunological signature is highly indicative of a true 
autoimmune response and allowed us to prioritize the RNPC3 and the minor spliceosome for 
follow-up analysis by IP-WB using full-length antigens that confirmed our initial findings. These 
results illustrate the usage of immunological understanding to recognize candidate autoantigens 
that are unlikely to simply be due to cross-reactivity or false positives. 
One striking feature of our results is that when we used PhIP-Seq to map the 
autoantibody epitopes in the 18 samples with autoantibodies against RNPC3 as detected by 
Western Blot, we found that almost all of these samples had autoantibodies against the same set 
of peptides in RNPC3. This pattern is highly reminiscent of our results with Virscan, in which 
the vast majority of people generated antibodies against the same viral peptides following 
exposure. As discussed in the preceding chapter, it is possible that this region of the protein 
exhibits particularly antigenic properties. Although not repetitive, the targeted region of RNPC3 
is fairly rich in amino acids that we found to be enriched in viral epitope determinants (12.5% P, 
12% E, 8.5% K, 7.1% D; Figure 17). It is possible that the antigenic features of this region of the 
protein elicit an immunodominant antibody response across individuals. However, our results do 
 106 
not rule out the possibility that highly similar antibodies arose in all of these individuals from a 
shared naïve B cell precursor, as discussed in the preceding chapter. 
The initial trigger for SSc is believed to be damage to the endothelial cells. Because the 
minor spliceosome complex is a nuclear antigen and should not be exposed on undamaged 
endothelial cells, autoantigens against the complex may not be directly involved in the initiation 
of disease. However, upon initiation of endothelial cell death, the nuclear antigens are released 
into the extracellular environment and could elicit an autoimmune response. Unfortunately, our 
data does not reveal whether the antinuclear autoantibodies are involved in pathogenesis or are 
merely a consequence of disease, a question which is still unanswered for most rheumatic 
diseases (106). Unlike patients with systemic lupus erythematosus, patients with SSc do not 
experience deposition of highly inflammatory immune complexes containing autoantibodies in 
affected tissues (107). However, treating patients with SSc with the B cell depleting monoclonal 
antibody Rituximab improves skin fibrosis and prevents worsening lung fibrosis, suggesting that 
the humoral response does play a role in pathogenesis (108). 
In the case of patients with SSc in the subclass with autoantibodies against Pol III, the 
autoantibodies appear to be a cross-reactive B cell response generated after a specific T cell 
response to a mutant Pol III neoantigen in a tumor (109). This model suggests that in these 
patients SSc develops due to aberrant tumor immunity and autoantibodies against Pol III play an 
early role in pathogenesis. It is possible a similar mechanism operates in the subclass with 
autoantibodies against the minor spliceosome complex. Although only half of the patients in this 
subclass had coincident cancer diagnosis, it is possible that the other half’s autoimmunity was 
also triggered by a tumor, but the tumor regressed before being diagnosed. Sequencing the genes 
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encoding members of the minor spliceosome in the tumors of patients in this subclass could also 
reveal tumor neoantigen driven autoimmunity. 
One interesting observation is that all of the subclasses of patients with SSc are mutually 
exclusive. It is possible this result is due to heterogeneity in the underlying cause. Perhaps SSc in 
the POLR3A subclass are all initiated by immunity against tumors with POLR3A mutations, 
whereas SSc in other subclasses are initiated by other mechanisms that elicit different 
autoimmune specificities. It is also possible that there is a genetic component. Patients with 
particular HLA alleles or polymorphisms in other immune-related genes may be predisposed to 
generate particular autoantibody specificites. Genome-wide associations studies have found that 
particular SNPs in HLA class II genes are associated with autoantibodies against topoisomerase 
1 or centromeres (110). 
Regardless of the mechanism of their origin, autoantibodies against the minor 
spliceosome complex could serve as a useful diagnostic and prognostic biomarker. It is already 
known that patients in the three known subclasses of SSc have very different clinical prognoses 
(97, 99–101). We can now study the medical records or conduct longitudinal studies of patients 
in the novel subclass to identify distinguishing clinical features. Knowledge of these clinical 
features may also inform understanding of the underlying pathogenesis. 
In this work, we used a pair of complementary antigen discovery technologies developed 
in our laboratory and discovered a novel subclass of patients with SSc who have autoantibodies 
against the minor spliceosome complex. These autoantibodies can serve as diagnostic and 
prognostic biomarkers for clinical care. Because over half of the patients in this subclass had 
coincident cancer diagnoses, we believe the autoantibodies may result from an anti-tumor 
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neoantigen immune response that cross reacts with the wild type, as previously reported for a 
known subclass of patients with SSc. 
Methods(
PhIP;Seq:(library(design,(construction,(assay,(and(analysis(
The PhIP-Seq autoantigen library sequences were derived from the RefSeq collection of 
human protein sequences and cloned into a T7 bacteriophage display system similar to what has 
been previously described (19). Briefly, the protein sequences for 90 amino acid protein 
fragments tiling with 45 amino acid overlap through all of the human proteins in RefSeq were 
synthesized as 300 bp oligonucleotides with 5’ and 3’ adapter sequences using a programmable 
DNA microarray.  These oligonucleotides were then cloned into the T7-Select 10-3b 
bacteriophage display vector and amplified in the BLT5403 according to the manufacturer’s 
protocol (Merck Millipore). Aliquots are frozen at -80ºC in 10% DMSO until use. 
PhIP-Seq assays were conducted as previously described (19). First, we blocked each 
well of a 96 deep-well plate with 1 mL of 3% BSA in TBST overnight on a rotator at 4ºC. To 
each pre-blocked well, we added sera or plasma containing approximately 2 µg of IgG 
(quantified using a Human IgG ELISA Quantitation Set (Bethyl Laboratories)) and 1 mL of the 
bacteriophage library diluted to approximately 2×105 fold representation (2×1010 pfu for a library 
of 105 clones) in phage extraction buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 6 mM 
MgSO4). We performed two technical replicates for each sample. We allowed the antibodies to 
bind the phage overnight on a rotator at 4ºC. The next day, we added 20 µL each of magnetic 
Protein A and Protein G Dynabeads (Invitrogen) to each well and allowed immunoprecipitation 
to occur for 4 h on a rotator at 4ºC. Using a 96-well magnetic stand, we then washed the beads 
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three times with 400 µL of PhIP-Seq wash buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
0.1% NP-40). After the final wash, we resuspended the beads in 40 µL of water and lysed the 
phage at 95 ºC for 10 m. We also lysed phage from the library before immunoprecipitation 
(“input”) and after immunoprecipitation with beads alone. 
We prepared the DNA for multiplexed Illumina sequencing using a slightly modified 
version of a previously published protocol (96). We performed two rounds of PCR amplification 
on the lysed phage material using hot start Q5 polymerase according to the manufacturer 
suggested protocol (NEB). The first round of PCR used the primers IS7_HsORF5_2 
(ACACTCTTTCCCTACACGACTCCAGTCAGGTGTGATGCTC) and IS8_HsORF3_2 
(GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCCGAGCTTATCGTCGTCATCC). The 
second round of PCR used 1 µL of the first round product and the primers IS4_HsORF5_2 
(AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACTCCAGT) and a 
different unique indexing primer for each sample to be multiplexed for sequencing 
(CAAGCAGAAGACGGCATACGAGATxxxxxxxGTGACTGGAGTTCAGACGTGT, where 
“xxxxxxx” denotes a unique 7 nt indexing sequence). After the second round of PCR, we 
determined the DNA concentration of each sample by qPCR and pooled equimolar amounts of 
all samples for gel extraction. Following gel extraction, the pooled DNA was sequenced by the 
Harvard Medical School Biopolymers Facility using a 50 bp read cycle on an Illumina HiSeq 
2000 or 2500. We pooled up to 96 samples for sequencing on each lane and generally obtained 
approximately 100 - 200 million reads per lane (1,000,000 to 2,000,000 reads per sample).  
We performed the initial informatics and statistical analysis using a slightly modified 
version of the previously published technique (19, 70). We first mapped the sequencing reads to 
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the original library sequences using Bowtie and counted the frequency of each clone in the 
“input” and each sample “output” (62). Since the majority of clones are not enriched we use the 
observed distribution of output counts as a null distribution. We found that a zero-inflated 
generalized poisson distribution fits our output counts well. We use this null distribution to 
calculate a p-value for the likelihood of enrichment for each clone. The probability mass function 
for the zero-inflated generalized poisson distribution is 
푃 푌 = 푦 = 휋+ (1 − 휋)(휃 휃+ 휆 푥'(푒'휃'푥휆), 푦 = 0(1 − 휋)(휃 휃+ 휆 푥'(푒'휃'푥휆), 푦 > 0 
We used maximum likelihood estimation to regress the parameters , , and  to fit 
the distribution of counts after immunoprecipitation for all clones present at a particular 
frequency count in the input. We repeated this procedure for all of the observed input counts and 
found that  and  are well fit by linear regression and  by an exponential regression as a 
function of input count (Figure 9). Finally, for each clone we used its input count and the 
regression results to determine the null distribution based on the zero-inflated generalized 
poisson model, which we used to calculate the -log10(p-value) of obtaining the observed count. 
To call hits, we determined the threshold for reproducibility between technical replicates 
based on a previously published method (70). Briefly, we made scatter plots of the log10 of the -
log10 (p-values) and used a sliding window of width 0.005 from 0 to 2 across the axis of one 
replicate. For all the clones that fell within each window, we calculated the median and median 
absolute deviation of the log10 of the –log10 (p-values) in the other replicate and plotted it 
against the window location (Figure 10). We called the threshold for reproducibility the first 
window in which the median was greater than the median absolute deviation. We found that the 
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distribution of the threshold –log10 (p-value) was centered around a mean of approximately 2.3. 
So we called a peptide a hit if the –log10 (p-value) was at least 2.3 in both replicates.  
PLATO:(library(construction,(assay,(and(analysis(
The PLATO library is a barcoded version of the one previously described (85). The 
vector pRDDEST described in that paper was modified by cloning a stretch of 30 random 
nucleotides (N’s) following the attB2 site and in-frame with the downstream TolA sequence. 
These barcodes were previously selected to contain only sequences without a stop codon by 
cloning them, in-frame, as 5’ fusions to an antibiotic resistance gene, transforming them into 
sensitive bacteria, and selecting for resistance. The human ORFeome v5.1 collection was cloned 
into this barcoded vector using Gateway Cloning as previously described (111). The resulting 
DNA was electroporated into DH10B cells according the manufacturer’s protocol (Invitrogen), 
which were grown on carbenicillin containing LB agar plates, and plasmid DNA was maxi-
prepped from the cells scraped from these plates and stored at -20ºC until use. 
The PLATO assays were performed as previously described (111). Briefly, the plasmid 
DNA was PCR amplified using the T7B (5’-ATACGAAATTAATACGACTCACTATAGGGA 
GACCACAACGG-3’) and TolAK (5’-CCGCACACCAGTAAGGTGTGCGGTTTCAGTTGC 
CGCTTTCTTTCT-3’) primers. The amplified DNA is PCR purified and in vitro transcribed 
using the RiboMAX large-scale RNA production system-T7 kit according to the manufacturer’s 
protocols (Promega). The RNA is purified using MegaClear according to the manufacturer’s 
protocols (Ambion) and 15 µg is used for 100 µL in vitro translation reaction using the RTS 100 
E. coli HY kit according the manufacturer’s protocols (5 Prime). 12.5 µL of the in vitro 
translation reaction is diluted in 85.5 µL of Selection Buffer [2.5 mg/mL heparin, 1% (wt/vol) 
BSA, and 83.3 µg/mL yeast tRNA in 50 mM Tris acetate and 150 mM NaCl, pH 7.5, DEPC 
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treated] and added to 40 µL of a 1:1 mix of Protein A and Protein G Dynabeads (Life 
Technologies) that have bound 2 µg of IgG from serum overnight at 4ºC in PBST containing 1% 
(wt/vol) BSA and subsequently blocked in RD Selection buffer for 1 hour at room temperature. 
After 4 hours of incubation with the in vitro translation product at 4ºC, the beads are washed six 
times with 500 µL RD wash buffer (50 mM Tris acetate and 150 mM NaCl, pH 7.5, DEPC 
treated) and the remaining bound RNA is eluted with 50 µL EB20 (50 mM Tris acetate, 150 mM 
NaCl, 20 mM EDTA, pH 7.5) at 37ºC for 10 min. The eluted RNA is purified using the 
MegaClear kit according to the manufacturer’s protocols (Ambion) and reverse transcribed with 
the TolART primer (5’-CGCTGCTTCTTCCGCAGCTTTAGC-3’) using the SuperScript III kit 
according to the manufacturer’s protocols (Life Technologies). The barcode region of the cDNA 
is then PCR amplified using the primers Adap-BCfor (5’-GTGACTGGAGTTCAGACGTGTGC 
TCTTCCGATCTACAAGTCACGTCCACAGTCGT-3’) and P5-BCrev (5’-AATGATACGGC 
GACCACCGAACTACGGTGCGGCGAATATAC-3’). The second round of PCR used 1 µL of 
the first round product and the primers P5-BCrev and a different unique indexing primer for each 
sample to be multiplexed for sequencing (CAAGCAGAAGACGGCATACGAGATxxxxxxxGT 
GACTGGAGTTCAGACGTGT, where “xxxxxxx” denotes a unique 7 nt indexing sequence). 
After the second round of PCR, we determined the DNA concentration of each sample by qPCR 
and pooled equimolar amounts of all samples for gel extraction. Following gel extraction, the 
pooled DNA was sequenced by the Harvard Medical School Biopolymers Facility using a 50 bp 
read cycle on an Illumina HiSeq 2000 or 2500. 
We first mapped the sequencing reads to the original library sequences using Bowtie and 
counted the frequency of each clone in the “input” and each sample “output” (62). We then used 
then used these sequencing read counts to calculate “fractional abundance” estimates for each 
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clone using the number of reads for that peptides divided by the total number of reads for that 
sample. The ratio of the fractional abundance in the output over the input is used as an estimate 
for fold-change enrichment. 
  
 114 
Chapter&5:&
Conclusion&and&Future&Directions&
 &
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Summary(
In this chapter, I will summarize the results of the work contained in this thesis and 
suggest directions for future research. 
In Chapter 2, I described a synthetic antibody library designed for high-throughput 
sequencing assisted selection. This method enables rapid in vitro selection of antibodies that bind 
specifically to a target of interest by bypassing the need for laborious single-clone screening for 
specific binding. We demonstrated application of this method to identify an antibody that binds 
specifically to a cancer-associated antigen.  
In Chapter 3, I describe VirScan, a high-throughput assay for detection of antibodies 
against all known human viruses. We showed that VirScan has very high sensitivity and 
specificity for detecting a range of viruses and then applied it to over 500 serum samples from 
donors across four different continents. We found that the antiviral antibody response in different 
individuals targets strikingly similar epitopes, suggesting that there may be antibodies, or at least 
antibody specificities, which are shared across the global human population. 
And last, in Chapter 4, I describe the use of the complementary approaches, PhIP-Seq 
and PLATO, to identify a novel subclass of patients with scleroderma. This subclass is mutually 
exclusive from the three previously known major subclasses and is characterized by 
autoantibodies against multiple components of the minor spliceosome complex. We also found 
some evidence that a significant portion of patients in this subclass may have developed 
autoimmunity in association with cancer. 
Improving(sequencing;assisted(selection(of(affinity(reagents(
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Although we were able to use our sequencing-assisted selection method to identify a 
synthetic antibody that specifically binds to the target of interest, the affinity of the antibody was 
rather weak. In addition, we found that the antibodies from our library were difficult to express at 
high yields. These drawbacks significantly limit the usefulness of our method. In this section, I 
describe ways to potentially overcome these limitations. 
There are several methods to carry out in vitro affinity maturation of antibodies (112). 
Since our system uses ribosome display, one simple method would be to use an error-prone 
polymerase to amplify the cDNA after reverse transcription of the eluted RNA. The error-prone 
polymerase introduces random mutations into the population after each round of affinity 
purification. Higher affinity antibodies arise from the population of mutants of initially weakly 
binding antibody. 
However, such random mutations pose an issue for high-throughput sequencing 
identification of individual antibodies. Because current high-throughput DNA sequencing 
technologies’ read lengths are still too short to sequence an entire antibody gene, our sequencing-
assisted method only reads the complementarity determining regions (CDRs). This is sufficient if 
the remaining portion of the antibody gene (framework sequences) is constant, which is true for 
our library design. However, it is not sufficient to identify antibodies if they contain important 
mutations introduced by an error-prone polymerase in the framework sequence, which is not 
sequenced. 
One possible method to restrict mutations to the CDRs (which will likely confer the 
greatest improvements in antibody affinity) is to amplify the CDRs independently with error 
prone polymerase, then use a combination of splicing by overlap extension (113) and Gibson 
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assembly (55) (or traditional cloning) to assemble the CDRs into the original framework. 
However, after independent amplification and re-assembly, an antibody may contain CDRs from 
multiple different parent antibodies instead of just mutated CDRs of the single parent antibody. 
Shuffling of heavy- and light-chain pairs is a commonly used technique for affinity maturation, 
but shuffling CDRs within heavy chains may be detrimental. 
Instead of affinity maturation during selection, another strategy is to improve the quality 
of the initial collection of synthetic antibodies. In particular, it is possible that only a relatively 
small proportion of the initial collection actually folded into functional antibodies. Previous 
structural studies showed that for a particular antibody framework, certain residues in the CDR-
H2 loop are buried and may be necessary for proper folding (114). Our library also used a single 
framework, but the CDR-H2 loops were designed using a Hidden Markov Model based on 
crystal structures of antibodies of multiple different frameworks. In addition, because this 
implementation of Markov Models was inherently memory-less, it did not take into account any 
amino acid preference at a specific position.  Thus, the CDR-H2 loops may not contain the 
proper residue at the normally buried positions for the specific framework we used, preventing 
the antibody from folding properly. If they constitute a significant percentage of the library, the 
effective size of the library would be much smaller and the probability of finding a high affinity 
antibody would be lower. It may be beneficial to design a library where only the solvent exposed 
residues on CDR-H2 are diversified. 
Going beyond just antibodies, there are also alternative protein scaffolds for affinity 
reagents with much more favorable properties, including adnectins, affibodies, anticalins, and 
designed ankyrin repeats (115). It is possible to develop affinity reagents using these alternative 
 118 
scaffolds which have very high affinity and specificity, but are much smaller than traditional 
antibodies (allowing full-length reads even with high-throughput sequencing), are more easily 
expressed at high yields even in bacteria, and do not require disulfide bonds and are thus 
functional intracellularly. Using these alternative scaffolds could improve the functional 
properties of the initial antibody library. 
Understanding(and(exploiting(recurrent(viral(B(cell(epitopes(
One of the most striking findings in our VirScan studies was that almost everyone 
generates antibodies that recognize the same or highly similar epitopes after exposure to a virus. 
We found this to be true for several different populations and several different viruses. Our 
results did not elucidate a biological mechanism for this phenomenon, but we think that there are 
likely two possibilities.  
The first possibility is that these recurrently targeted epitopes possess special properties 
that make them particularly antigenic. In our studies, we showed that peptides recognized by 
antibodies tended to share a slight compositional bias. However, we did not observe any 
statistically significant enrichment for surface antigens or terminal peptides among viral peptides 
recognized by antibodies. These results suggested that these properties of the peptide are not 
sufficient to explain highly recurrent epitopes, but it is a possibility that a combination of these 
properties perhaps in conjunction with properties we did not test for are critical determinants of 
antigenicity. 
The second possibility is that the recurrently targeted epitopes we observe are actually the 
result of the same or highly similar antibodies arising across individuals. In fact, there is already 
some evidence for this possibility from high-throughput sequencing of antibody genes. Although 
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these methods rarely identify identical antibody sequences in unrelated individuals, even high-
throughput sequencing only samples a small subset of the entire antibody repertoire so the 
absence of identical sequences may be due to undersampling (7). One study, which focused on 
analyzing very deep sequencing of antibodies against dengue virus, found that highly similar or 
even identical CDR-H3 sequences were present in multiple individuals (95). CDR-H3 is the most 
diverse CDR and the probability of observing such similarity by chance alone is infinitesimally 
small. Thus, these results suggest that the process for generating antibodies is not random but 
highly biased such that identical or nearly identical antibodies can frequently arise in multiple 
individuals. In fact, it is known that VDJ recombination and even addition of N and P 
nucleotides are highly biased such that certain rearrangements are much more highly favored 
(94). 
Distinguishing between these possible explanations for our observations will require 
sequencing of the genes of antibodies from multiple individuals that recognize the same 
recurrent epitope to determine if the antibody sequences are truly identical or highly similar. 
Because we have identified the recurrent epitopes, we can use them to sort for B cells that 
express membrane-bound B cell receptors that recognize the epitope. We would do this for B 
cells from multiple individuals and sequence the sorted B cell’s antibody gene. Identical 
sequences across individuals would suggest that at least a portion of the antibodies generated by 
humoral immune system are not completely random as generally believed. It is possible that the 
inherent biases in antibody gene rearrangement were evolutionarily selected to ensure production 
of antibodies that recognize epitopes on common viruses. 
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Knowledge of these highly recurrent epitopes could be used to create a more focused 
version of VirScan optimized for rapidly diagnosing viral infections. In the paper, we showed 
that on average approximately 1% of a virus’s peptides are recurrent and that the recurrent 
peptides alone can actually increase the sensitivity and specificity of diagnosing certain viral 
infections. Thus, for applications that focus on diagnosis, it may be possible to assay 100-fold 
fewer peptides without sacrificing performance. 
With such few peptides, it should be possible to use a peptide microarray instead of 
bacteriophage display for the assay. Peptide microarrays contain peptides synthesized or 
immobilized on specific locations on a solid substrate (116). Serum antibodies are allowed to 
bind to the peptides and a secondary antibody is used to visualize which peptides the serum 
antibodies bind. The advantage of peptide microarrays is the assay time is much faster than with 
high-throughput sequencing, which may be important in a clinical setting. Using a secondary 
antibody for IgM antibodies can distinguish between acute infection and long-term antibodies, 
since IgM antibodies are generally only found in the early stages of the adaptive immune 
response. 
It may also be possible to use the knowledge of these highly recurrent epitopes to 
enhance efficacy of vaccines. In particular, we believe these epitopes can be fused to subunit 
vaccines to elicit immune complex formation in vivo, which should increase the potency of the 
immune response. 
Immune complexes are composed of antibodies bound to soluble antigens. They can 
enhance the humoral immune response by activating the complement cascade (117), promoting 
Fc-receptor mediated endocytosis and antigen processing by antigen presenting cells (118), and 
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enabling Fc-receptor mediated presentation of antigens on follicular dendritic cells for selection 
and affinity maturation of B cells (119). 
Vaccination with pre-formed immune complexes is known to enhance primary and 
secondary antibody responses to model antigens as well as viruses such as hepatitis B virus and 
human immunodeficiency virus (120, 121). However, production of immune complex vaccines 
is difficult because it requires formulating an antigen in complex with an antibody that binds it. 
In our paper, we reported highly recurrent epitopes from very common human viruses. 
Over 90-95% of the samples we studied had antibodies against these epitopes. If these highly 
recurrent epitopes are fused to an antigen for vaccination, the fused antigen should form immune 
complexes in vivo with pre-existing antibodies against the recurrent epitope. With this method, 
no exogenous antibodies are required because it “piggybacks” on the antibodies that are already 
present in the vast majority of the population. In fact, except for adding a short sequence to the 
gene encoding the antigen, the rest of the vaccine manufacturing process can be left unchanged, 
allowing production to occur essentially using currently established methods and facilities. This 
simple modification should be compatible with standard manufacturing procedures and could 
significantly improve the efficacy of current and future vaccines. 
Mechanistic(studies(of(scleroderma(subclasses(
We discovered a novel subclass of patients with scleroderma who have autoantibodies 
against the minor spliceosome complex. Using the complementary approaches PhIP-Seq and 
PLATO, we detected autoantibodies against many, but not all of the components of the complex. 
It would be interesting to use other approaches, perhaps ELISA or IP-Western with proteins 
expressed in human cells, to determine the extent of epitope spreading within this complex. 
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Knowing the extent of autoimmunity against the minor spliceosome complex will also 
inform experiments to determine this subclass’s association with malignancy. Approximately 
half of the patients in this subclass had coincident diagnoses of cancer and scleroderma. A 
previous study showed that in patients with autoantibodies against Pol III, the autoantibodies are 
a result of an immune response against a tumor-associated mutant POLR3A gene that cross-
reacts with the wild-type protein (26).  
To look for evidence of a similar mechanism operating in the newly discovered subclass, 
we could take tumor biopsies from the patients with coincident diagnoses of cancer and 
scleroderma and sequence the genes encoding components of the minor spliceosome complex. 
As a control, we could sequence the same genes in patients with coincident diagnoses but no 
autoantibodies against the minor spliceosome complex. If genetic alterations in these genes were 
only found in patients with autoantibodies against the minor spliceosome, it would suggest that 
the alterations might trigger a cross-reactive response. Because the mutant sequence is known, it 
would then be possible to look for mutant-specific immune responses that may have preceded 
autoimmunity. 
Knowledge of this novel subclass could also be used for clinical purposes. Our results 
indicate that autoantibodies against the RNPC3 gene product is found specifically in patients 
with scleroderma and not in healthy people or patients with other autoimmune diseases. Thus, 
this autoantibody specificity could be a useful diagnostic biomarker for scleroderma, which can 
be difficult to diagnose. In addition, the three previously characterized subclasses are known to 
be associated with different disease severities (97, 99–101). Studies of the onset and progression 
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of disease in the novel subclass may also reveal that this autoantibody specificity would be a 
useful prognostic marker as well. 
The(study(of(adaptive(immunity(needs(high;throughput(tools(
The incredible flexibility and specificity of the antibody response is dependent on the 
highly diverse repertoire of naïve and affinity-matured antibodies. Utilizing and understanding 
the power of this response requires high-throughput approaches. In addition, the immune system 
is exposed to a wide variety of environmental antigens and a host of ever-evolving 
microorganisms. Although model antigens and inbred organisms are powerful tools, native 
immune responses are much more complex. The combined diversity of possible antibody-antigen 
combinations present formidable challenges for study, but, as described in the projects of this 
thesis, new techniques that take advantage of the rapid advances in DNA sequencing and 
synthesis can enable investigations of this complexity at unprecedented depth. 
In addition to purely DNA sequencing-based studies of the host immune response, 
creating large collections of antigens of interest using DNA synthesis enables a much more 
complete picture of the immune system in the context of antigen exposure. The tools used and 
described in this thesis – PhIP-Seq, PLATO, and VirScan – provide complementary approaches 
to tackling the diversity of the antibody response to viral and autoantigens.  
Beyond the humoral response, the adaptive immune response also has a cellular 
component mediated by T cells. Similar high-throughput approaches could be developed to study 
these responses, but they will require the development of a novel assay format because T cell 
receptors are always membrane bound, are generally lower affinity, and recognize their antigen 
in the context of the major histocompatibility protein on the surface of an antigen presenting cell. 
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The combination of such a method with the ones described in this thesis will enable a much 
greater understanding of the complex interplay within the adaptive immune response in infection 
and autoimmunity.  
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Appendix&A:&
Recombination&of&barcoded&libraries&
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In this appendix section, I describe the design and implementation of a strategy for the 
recombination of two barcoded DNA libraries that enables unique identification of the 
recombined pairs of DNA using high-throughput short read sequencing of the adjacent barcodes. 
In this dissertation, I have described several applications of the power of high-throughput 
sequencing for identifying members of a population that are enriched in selection experiments. 
This approach works very well for constructs encoded by short nucleic acid sequences, since 
most high-throughput sequencing technologies have a relatively short maximum read length and 
pursuing longer read lengths comes at the cost of the number of reads, limiting the complexity of 
the libraries which can be screened. Thus for larger constructs, such as full length ORFs, our 
laboratory has begun using barcoded DNA libraries, in which the ORFs are paired with a short 
DNA barcode during cloning. These barcodes uniquely identify the ORF, thus overcoming the 
limitations of the sequencing technologies. In addition, amplifying just the barcodes instead of 
full length ORFs limits the introduction of PCR biases. 
This approach requires an initial paired-end sequencing step to map which barcodes 
correspond to which embers of the library (ORFs, in this case). Because the ORFs have very 
different sequences, even short reads which cover only a fragment of the ORF can uniquely 
identify it. However, this approach would not work if the members of the library shared 
significant sequence similarity, for example with a paired ORF library, where one ORF could be 
paired with many other ORFs, or a recombinant antibody library in which the one heavy chain 
sequence could be paired with many other light chain sequences. This is because the sequencing 
technologies have a limit on the maximum size of the amplicon. So the paired end sequencing 
would only be able to read the barcode and the proximal DNA fragment, but that isn’t enough for 
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unique identification because the same proximal DNA fragment can pair with multiple different 
distal DNA fragments. One strategy would be to introduce restriction sites flanking the proximal 
DNA fragment such that cutting and intramolecular ligation would bring the barcode and the 
distal DNA fragment closer, but this is a laborious process that may introduce biases and would 
need to be performed before each sequencing step. Instead, we chose to develop a library 
construction strategy that utilizes recombination of two separately barcoded libraries which 
results in adjacent barcodes identifying the constructs from both libraries so that a simple PCR 
will capture both adjacent barcodes which uniquely identify the members of both libraries. 
The strategy builds on the mating-assisted genetically integrated cloning (MAGIC) in 
vivo cloning technology previously developed in our laboratory (122). Briefly, MAGIC uses the 
E. coli transfer system of F factor (F’) to conjugate a donor plasmid with a conditional origin of 
replication (R6K oriγ) and an insert flanked by 50 bp homology arms and a rare cleavage site 
(for I-SceI) from a permissive host to a non-permissive host that expresses the endonuclease I-
SceI and the lambda-Red recombination system with a recipient plasmid containing the same 
homology arms flanking the rare cutter sites. The I-SceI cuts the donor and recipient plasmids 
and the lambda-Red recombination system recombines the insert fragment into the recipient 
plasmid. Appropriate selectable markers on the insert and donor DNA allow selection for the 
recombined product. 
MAGIC is very efficient, but to increase it’s efficiency even further, I substituted M13 
phage instead of conjugation to transfer the donor plasmid to the recipient strain. This required 
the introduction of the phage f1 origin or replication into the donor plasmid and packaging using 
a standard M13 helper phage. I also placed the barcodes for the insert and recipient DNA directly  
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Figure 33. Schematic for barcoded DNA library recombination strategy. The donor E. coli strain (top right) 
expresses a relaxed copy-number control allele of the trans-acting factor π encoded by the pir1-116. This factor is 
necessary for the replication of the donor plasmid which is under the control of R6K ori γ. The donor plasmid 
contains a chloramphenicol resistance gene (camR), followed by a gene of interest (GOI1) and a barcode (BC1). 
This sequence is flanked by two 50-bp homology arms (H1, H2) and I-SceI sites (inverted black triangle). Finally 
the donor plasmid also contains an f1 ori for packaging in M13 phage. This phage is used to infect the recipient 
strain (top left). The recipient strain is deficient in pir1-116 but expresses I-SceI and the lambda red 
recombination proteins under inducible control. The recipient plasmid contains a single I-SceI site flanked by the 
same two homology arms (H1, H2) and a second gene of interest (GOI2). Following infection and induction of I-
SceI and the lambda red proteins (bottom), the insert from the donor plasmid will recombine into recipient 
plasmid, bringing the barcodes together and the genes of interest together into one vector.  
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adjacent to the homology arms. Finally, I included a selectable marker (chloramphenicol 
resistance gene) and a separate restriction site in the insert DNA so I could easily assay for 
successful recombination (Figure 33). 
After infection and induction of I-SceI and the lambda Red gene, I plated the cells on 
amipicillin (selectable marker for the recipient plasmid) and obtained approximately 108 cfu/mL, 
consistent with the optical density of the cultures (see Methods). Then, I replica-plated 48 
colonies onto plates containing ampicillin and chloramphenicol to assay for the presence of the 
insert DNA. I repeated this procedure three times and obtained between 12 and 19 ampicillin- 
and chloramphenicol-resistant colonies, suggesting that the recombination efficiency is between 
25-40%. In one replicate, I also picked 10 of the resistant colonies to miniprep and performed a 
double digest using restriction enzymes that cut once each in the recipient and donor plasmid. In 
all 10 colonies, the double digest resulted in the banding pattern predicted for the recombined 
product (Figure 34). Finally, I sequenced the DNA from these 10 colonies, which confirmed that 
all 10 were properly recombined. 
These results indicate that the recombination is highly efficient. In addition, substituting 
M13 phage for conjugation greatly improved efficiency. The original MAGIC paper 
demonstrated approximately 2*106 cfu/mL recombinants, whereas with M13 phage, I was able to 
obtain 2.5-4.0*107 cfu/mL, an increase of over an order of magnitude. This strategy will be 
useful for constructing barcoded DNA libraries for sequencing-assisted selections. 
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Methods(
To prepare the donor phage, the donor strain BUN20 (122) containing the donor plasmid 
was grown at 30 ºC in Luria-Bertani broth containing 12.5 µg/mL of chloramphenicol to 
A600=0.3. M13K07 helper phage was added at an MOI of 20:1 and the culture was allowed to 
incubate at 30 ºC for another 30 min. 50 µg/mL of kanamycin was added to the culture and 
grown overnight. The overnight culture was centrifuged at 10,000 g for 10 min and the 
supernatant was supplemented with one volume of 2.5 M NaCl/20% PEG-8000 for each four 
volumes of supernatant. The mixture was allowed to sit for 30 min at 4 ºC and then centrifuged 
for 10,000 g for 10 min and the precipitant was resuspended in 1/10 the volume of PBS. This 
mixture of M13 phage was then titered using the standard protocol. 
To perform the recombination, the donor strain BUN21 containing the recombination 
plasmid pML104 and the recipient plasmid (122) was grown overnight at 30 ºC in Luria-Bertani 
Figure 34. Restriction digest of recombinants. The first lane is a molecular weight ladder. The next ten are 
individual ampicillin and chloramphenicol resistant colonies following double-digest. The last lane is the recipient 
plasmid following double digest. The arrows indicate the predicted size of the restriction digest products. 
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supplemented with 100 µg/mL of ampicillin, 50 µg/mL of spectinomycin, and 0.2% w/v of 
glucose. Following overnight growth, the culture was washed twice in two volumes of Luria-
Bertani broth. The recipient strain was then diluted 1:200 in Luria-Bertani broth and grown to 
A600=0.15-0.25, at which point the donor phage was added at an MOI of 20:1. The media was 
supplemented with 0.2% w/v L-arabinose and the culture was incubated at 37 ºC for 2 h without 
shaking followed by 2 h with shaking. Serial dilutions of the cultures were grown overnight at 42 
ºC on selection plates containing 100 µg/mL of ampicillin. 
 &
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